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Aurora Cancer Care
In the past five years, Aurora Cancer Care has experienced a 17% growth in new patients. Each year additional experienced, fellowship-trained physicians
and cancer care experts are recruited. Technology and system-wide collaborations and programs are continuously improved and updated to ensure best
practices are developed through evidence-based pathways. Aurora Cancer Care is committed to providing the most efficient, effective, affordable quality
cancer care with innovative health care solutions to provide patients with the best possible outcomes.

Aurora Cancer Care
is the largest cancer
program in Wisconsin.
One in every four patients
diagnosed with cancer
in the state of Wisconsin
comes to the cancer experts
and clinical teams at
Aurora Cancer Care.

Our team of world-class
specialists is here for you
to bring hope and the
answers you need.
From initial diagnosis to
treatment and follow up,
our coordinated approach
is designed to give you
the very best care,
all in one place.

Aurora Cancer Care
has extensive cancer
screening, prevention,
cancer nurse navigation,
treatment, and survivorship
programs. We treat patients
using cutting edge
technology that no other
health care systems in
Wisconsin have.
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Cancer Care Close to Home
Aurora Cancer Care’s 154 oncology physicians
currently care for over 25,500 patients with
cancer, including over 8,100 newly diagnosed
patients annually. Aurora Cancer Care is able to

Wisconsin

Our
Service
Areas

Michigan

= Hospital
= Aurora Psychiatric Hospital.
Behavioral Health is a Patient
Service Area without
geographical boundaries

Green Bay,
Manitowoc
& Marinette

provide patients care close to home
through our 19 medical oncology locations
and

North Region

11 radiation oncology treatment locations

throughout eastern Wisconsin and northern Illinois.

Oshkosh
& Fond du Lac

Greater Milwaukee North
& Sheboygan

Central Region

Waukesha
& Jefferson

Greater
Milwaukee South

Wisconsin
Illinois
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Burlington
& Walworth
Racine,
Kenosha
& Northern
Illinois

South Region

Awards & Recognitions
Aurora Cancer Care is committed to providing patients with the highest-quality, personalized care. We accomplish this by adopting best practices
designed around evidence-based national standards for quality and care as determined by multiple accrediting organizations. In addition, many
of our oncology physicians have received national recognition through American Society of Clinical Oncology (ASCO) for their expertise.

ASCO NATIONAL RECOGNITION
Dr. Michael A Thompson
2016-2017 – Chair ASCO Education Committee
2016-2017 – Chair ASCO Research Community Forum
Dr. Michael Mullane
2017-2018 – Track Leader, ASCO Cancer Prevention,
		
Hereditary Genetics, and Epidemiology
Dr. Federico Sanchez
2017-2018 – Track Leader, ASCO Education, GI, non-CRC
Dr. Elizabeth Dickson-Michelson
2017-2018 – Track Leader, ASCO Education, GYN-ONC
Dr. Nicholas Webber
2017-2018 – Track Leader, ASCO Education, Sarcoma
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BY THE
NUMBERS

Top 12 Volume Wisconsin Health Systems
Hospital Utilization for Cancer Care by Volume
2015
0

Wisconsin Hospital Utilization for Cancer Care - Top
Volume Health Systems Cancer Cases Based on
Primary (ICD) Diagnosis
2015

2016

Aurora Health Care

12,104

12,513

13,209

Ascension Health

9,656

8,965

8,879

UW Health

8,440

8,689

8,629

Froedtert Health

4,589

4,671

5,053

Hospital Sister's Health

3,122

2,977

2,929

SSM Healthcare

2,633

2,663

2,776

Thedacare

2,239

2,476

2,605

ProHealth

2,307

2,370

2,471

Mayo Clinic Health

2,083

2,169

2,456

Aspirus

2,010

2,128

2,252

Gundersen Health

1,894

2,094

1,939

Bellin Health

1,393

1,475

1,479

HEALTH CARE SYSTEM

2017

Aurora
Health Care
Ascension
Health
UW
Health
Froedtert
Health
Hospital Sister's
Health
SSM
Health

Thedacare

ProHealth
Mayo Clinic
Health
Aspirus

Source: WHA 2015 - 2017

Gundersen
Health
Bellin
Health
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Cancer Types Diagnosed at Aurora Cancer Care
Primary Site 2016
HEAD & NECK		

238

RESPIRATORY SYSTEM

892

MALE GENITAL		

966

Oral Cavity

67

Lung/Bronchus

877

Prostate

921

Oropharynx

62

Other

15

Testis

38

Major Salivary Gland

14

Other

7

Nasopharynx

3

BLOOD & BONE MARROW

467

Hypopharynx

12

Leukemia

279

Larynx

57

Multiple Myeloma

Nasal/Paranasal

8

Other

15

ENDOCRINE			

228

Thyroid

160

Other

68

DIGESTIVE SYSTEM

1133

Esophagus

80

Stomach

85

Colon

378

Rectum

144

Anus/Anal Canal

34

Liver

99

Pancreas

179

Other

134

URINARY SYSTEM		

701

Bladder

394

92

Kidney/Renal

284

Other

96

Other

23

BONE				

11

CONNECT/SOFT TISSUE

48

BRAIN & CNS		
Brain (Benign)

506
39

SKIN				

406

Brain (Malignant)

68

Melanoma

348

Other

399

Other

58

LYMPATHIC SYSTEM

336

Hodgkin's Disease

38

BREAST			

1301

Non-Hodgkin's

298

FEMALE GENITAL		

577

UNKNOWN PRIMARY

65

Cervix Uteri

61

OTHER/ILL-DEFINED

43

Corpus Uteri

304

Ovary

126

Vulva

57

Other

29
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Message from the Vice President
Aurora Cancer Care has shown significant growth and broadening of our services over
the past five years and this continues to accelerate. During this time our medical
oncologists have subspecialized, recognizing the explosive growth of new research and
cancer treatments. This has also allowed us to provide valuable internal in-depth
consultation across the system. Aurora Cancer Care’s successful recruitment of patients
into our National Cancer Institute Community Oncology Research Program (NCORP)
trials has been recognized by the National Cancer Institute (NCI) with nearly $500,000
of additional award money given to Aurora, in addition to our original $3.8 million
NCORP grant. We were recognized with Platinum (Virani) and Gold (Mullane) award
winners for patient accrual into NCORP trials and an additional 11 of our physicians
received honorable mentions. VIA oncology pathways have been successfully integrated into our Electronic Medical Record by their incorporation into Beacon and EPIC. Our
group runs approximately 85% on pathway. The placement of clinical trials as the first
pathway option has resulted in a 150% increase in patients placed on clinical trials since
the year before VIA and NCORP were introduced at Aurora. In addition, seven of the 18
medical disease committees of VIA are co-chaired by Aurora medical oncologists. Under
the leadership of Aaron Chevinsky, MD, new chief of surgical oncology, extensive work
has been done to standardize the work up and treatment of gastrointestinal cancers and
breast cancers across the system. He will also lead incorporation of VIA’s surgical
oncology pathways into management of patients with breast and pancreatic cancer
this year.

James Weese, MD
Vice President, Aurora Cancer Care
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Aurora Cancer Care members have received significant national recognition,
raising the profile of our Cancer Service Line. Michael Thompson, MD, PhD, received
great recognition and accolades for his leadership of the American Society of Clinical
Oncology (ASCO) education committee for the 2017 ASCO national meeting. Many of
our physicians also spoke and chaired sessions at ASCO. Leadership continues with Dr.
Thompson as the immediate-past-chair of education, as well as track chair leaders for
cancer prevention, hereditary genetics, and epidemiology (Mullane),
gastrointestinal-noncolorectal (Sanchez), gynecologic cancer (Dickson-Michelson),
and sarcoma (Webber). Our medical oncology program continues as one of the
largest programs in the country that has achieved ASCO’s quality certification through
their Quality Oncology Practice Initiative (QOPI) program. Aurora Cancer Care was
recertified by QOPI in 2017 for another three years.

The importance of patient education was highlighted by Aurora Cancer Care being awarded the Innovator Award by the Association of Community Cancer
Centers. This reflected over 125 individual therapy videos made by our oncology certified nurses (OCNs) and oncology pharmacists to ensure that patients
across all of our sites receive consistent chemotherapy/immunotherapy education.
In 2016, I had the privilege of attending the National Cancer Moonshot Summit on an invitation from Vice President Joe Biden. The Summit brought together
more than 350 oncologists, researchers, data and technology experts, cancer patients, patient advocates, and others involved in cancer research and patient
care. The meeting, held at Howard University in Washington, D.C., focused on precision medicine, data sharing, and collaboration as strategies to advance
cancer research and treatment.
President Barack Obama announced the $1 billion National Cancer Moonshot initiative on January 12 during his 2016 State of the Union address and
appointed Vice President Joe Biden to lead it. The initiative’s goal is to double the pace of advances in cancer prevention, diagnosis, and treatment — in
other words, making strides in five years that used to take ten years. There was a particular focus on data sharing and earlier release of information about
new discoveries.
Precision medicine is a major focus of where the field of cancer research and treatment is moving. Our ability to identify genetic markers within a cancer’s
DNA is becoming a powerful tool in the development of new therapies. Because these new treatments can be extraordinarily expensive, it becomes critically
important to identify those patients whose tumors are most likely to respond to the new agents. In this capacity, Aurora Cancer Care is analyzing the genetic
makeup of cancer patients’ tumors to help oncologists determine exactly which treatments will likely work best for each individual patient. Such a
customized approach to cancer is called precision medicine. This will become increasingly important, and we anticipate it will yield significant progress,
particularly in patients with advanced disease over the next few years. To ensure Aurora Cancer Care remains at the forefront of this field we have adopted
use of the Syapse platform which will share our de-identified data with that of nine other health care systems so that we can see the treatment results of
genetically similar tumors in patients across the country. This data will be available to us in real time rather than having to wait the typical two to three years
for publication. This will allow us to select those new treatments most likely to benefit patients treated at Aurora. Our precision medicine clinic, started in
March 2017, has exceeded our anticipated one-year accrual of patients by 60% in just the first six months of operation. This clinic is led by Dr. Thompson and
Jennifer Godden, Pharm.D.
Precision medicine can also help identify patients who are at risk of serious adverse effects from cancer treatments, such as heart failure. At Aurora’s new
Karen Yontz Center for Cardio-Oncology, for example, physicians can determine a patient’s risk for developing heart disease after cancer treatment by
assessing the patient’s medical history and genetic profile.
These and many other exciting initiatives have resulted in a nearly 17% increase in new patients seen over the past five years at Aurora Cancer Care. At this
time, nearly one of every four patients diagnosed with cancer in Wisconsin is seen at an Aurora facility.
We are very proud of the many accomplishments outlined in this annual report and look forward for continued success and growth in the future.
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COMPREHENSIVE
CANCER CARE

10

Multidisciplinary Cancer Care
A diagnosis of cancer can bring about many emotions and questions.
The multidisciplinary cancer care approach at Aurora Cancer Care
provides patients and their families with a collaborative team of
world-class specialists to work together to work together to bring hope
and provide answers to meet patient needs.

•

The multidisciplinary team members can include:

MULTIDISCIPLINARY CANCER CLINICS

•
•
•
•
•
•
•
•
•
•
•

Medical oncology
Financial counseling
Radiation oncology
Genetic counseling
Surgical oncology
Nutrition counseling
Interventional radiology
Pain management
Pathology
Pastoral care
Aurora Behavioral Health

•
•
•
•
•
•
•
•
•
•

Rehabilitation
Cancer counseling
Resource library
Cancer nurse navigators
Social workers
Clinical research trials
Support services
Integrative Medicine
Survivorship programs
Diagnostics and imaging

MULTIDISCIPLINARY CANCER CONFERENCES
Aurora Cancer Care has developed system-wide multidisciplinary cancer
conferences. These conferences are an opportunity for Aurora physicians
to present patient cases to colleagues from anywhere within Aurora.
Technology has enabled us to conduct these conferences, not only in
person, but also via high-definition video conferencing. This advancement
creates a greater opportunity for attendance for all caregivers involved
which translates greater involvement to:
•
•
•

•

Add to their knowledge base in cancer care management by		
interaction with colleagues; and
Become aware of available clinical trials that their patients 		
may be eligible for participation.

Aurora Cancer Care is committed to providing patients with an
unparalleled level of care and an exceptional patient and family
experience. Our doctors come from every cancer field, and work as
a team to provide a coordinated approach that is specific to each patient.
Our multidisciplinary cancer clinics are designed to give the patient the
very best care, all in one place:
•

•

•

•

Patients meet with their entire cancer team during the first		
appointment – making things easier for patients during 		
their appointment.
The cancer team will review each patient's case and develop an
effective treatment plan based on National Comprehensive Cancer
Network guidelines, a national organization dedicated to improving
the quality and effectiveness of cancer care. The plan will be		
personalized to each patient and their cancer.
The cancer team will explain test results, discuss recommended
treatment options, listen to questions, concerns and fears, and will
develop a partnership that enables the patient and family to 		
participate in their care.
Newly diagnosed cancer patients can leave the clinic with a		
comprehensive plan for their work up and treatment.

Discuss the most current and appropriate medical 			
management strategies;
Stay current with evidence-based practices to provide improved
outcomes for patients;
Apply treatment plans agreed upon by consensus at the conference
to their patients;
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Prevention Screening Diagnosis & Treatment
Creating awareness about the
importance of screening for at-risk
diseases is the first step in
early detection. Our cancer experts
follow a uniform approach using
evidence-based national guidelines
for best care practices.
Prevention and screening is a
system-wide collaborative effort
among:
•
•
•
•
•
•
•
•
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Community Outreach
Primary Care Physicians
Women’s Health
Population Health
Dermatology
Wellness Programs
Surgery
Gastroenterology

If cancer is diagnosed by a primary
doctor, the patient may be referred
to cancer specialists. One doctor will
lead treatment, and all providers will
work together as a team to provide
the best care. Depending on where
the tumor originated, the care team
may include some of the following
specialties:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Gynecological Oncologist
Hematologist
Medical Oncologist
Neurologist
Occupational Therapist
Pathologist
Plastic Surgeon
Physical Therapist
Primary Physician
Pulmonologist
Radiation Oncologist
Registered Nurse
Surgeon (Thoracic, Breast, GI)
Urologist
Gastroenterology

Survivorship

Support Care
Patients may be referred to other
caregivers who are available at the
doctor's request. Patients and loved
ones may request care from the
following caregivers:
•
•
•
•
•
•

•
•
•
•
•
•
•
•

Cancer Nurse Navigator
Chaplain
Child Life Specialist
Clinical Nurse Specialist
Clinical Research Nurse
Complementary Therapists
(Massage, Aromatherapy,
Acupuncture, Reiki)
Dietitian
Financial Counselor
Genetic Counselor
Palliative Care Specialist
Pharmacist
Psychologist, Counselor
Rehabilitation Specialist
Social Worker

Cancer specialists remain on patient
care teams throughout survivorship.
A care plan will be suggested and
patients will continue to see their
primary physicians and surgeons as
needed. Patients may also continue
with caregivers such as:
•
•
•
•
•
•
•
•
•
•
•
•

Nurse Practitioner
Integrative Medicine
Acupuncturist
Massage Therapist
Reiki
Yoga
Tai Chi
Physical Therapy
Spiritual Counselor
Psychologist, Counselor
Financial Counselor
Dietitian

Cancer Care Team
2015
The treatment Aurora Cancer Care provides patients is not only top-notch, personalized cancer care, but it includes
integrated care for the whole person. Cancer care is a collaboration among several departments to help patients from
prevention through outreach and wellness programs, to early detection by working with primary care
physicians, women’s health, and dermatologists to develop best practices for cancer screening, to diagnosis
2014
in coordination with radiology and surgical oncology, to treatment with a multidisciplinary team of
surgical oncology, medical oncology, radiation oncology, and interventional oncology, to survivorship to
ensure the best possible post-treatment care through cancer rehabilitation, spiritual care, counseling
services, survivorship programs, and support groups. This is a process that is all guided by Cancer Nurse
Navigators to ensure patients are on the appropriate path through diagnosis and treatment in the most
efficient manner possible.

CANCER NURSE NAVIGATORS

2016

6,194

4,118

Unique
Patients

Facing a cancer diagnosis can be overwhelming to patients and their loved ones.
Once diagnosed, a patient is often presented with large amounts of new information
and have to quickly make a decision on treatment plans.
Cancer Nurse Navigators are nurses who serve as advocates, helping to guide patients
through the health care system and provide emotional support throughout diagnosis,
treatment, and survivorship. Our Cancer Nurse Navigators will listen to concerns,
help patients understand what to expect of any tests or treatments, answer questions,
and provide the resources needed to make informed decisions about care.

Our Cancer Nurse Navigators effectively and
efficiently provide patients with help in everything
from understanding the diagnosis and treatment
options, to coordinating appointments, to providing
support along the way.

7,913

2015

2014

2016

21,453
12,478

Patient
Contacts

26,933
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Surgical Oncology

Medical Oncology and Hematology

Our board-certified, fellowship-trained general, breast, gynecologic,
colorectal, thoracic, neuro, head and neck and musculoskeletal surgical
oncologists provide the most advanced therapies and surgical treatments
available, including minimally invasive options that reduce recovery times
and get patients back faster to what matters most in life.

The medical management of cancer care is provided by our		
board-certified medical oncologists and hematologists to address all
aspects of health.

Our comprehensive resources include:
		 – Minimally invasive surgery
		 – Laparoscopic surgical approaches for cancer and
			benign conditions
		 – Robotic-assisted surgery for treating esophageal, lung, 			
			 gynecologic, urologic, pancreatic, gastrointestinal and head 		
			 and neck issues, in addition to performing cranial and
			spine neurosurgery
		 – Video-assisted thoracoscopic surgery (VATS)

•

•
•
•
•
•
•
•

•

•
•
•
•
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The only Robotic Thoracic Surgery Training Center in Wisconsin
Sentinel lymph node biopsies to determine if cancer has spread
to the lymphatic system
Nipple-sparing mastectomy
Transoral laser surgery
Microsurgery
Plastic/reconstructive surgery
Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a 		
concentrated and heated treatment delivered directly to
the abdomen during surgery
Intraoperative Radiation Therapy (IORT), which delivers a 		
concentrated dose of radiation to the tumor site during surgery,
immediately after a cancer tumor has been removed
NanoKnife®, which uses electrical currents to destroy cancerous
tumor cells
Cryotherapy
Radiofrequency
Microwave Ablation

•

•
•
•
•
•

All board-certified medical oncologists with subspecialization
in specific types of cancers
Board-certified hematologists with expertise in cancer
and benign diseases of the blood
Immunotherapy treatment options that stimulate the body’s 		
immune response to fight disease
Chemotherapy infusion areas with comfort and support in mind
Clinical trials through the National Cancer Institute (NCI)
Community Oncology Research Program (NCORP)
Experienced nurses for chemotherapy and biotherapy administration
who are certified by the National Oncology Nurse Society (ONS)
Autologous bone marrow stem cell transplant, which uses a patient's
own stem cell as part of their treatment

Radiation Oncology

Interventional Oncology

Radiation therapy is an important tool for the treatment of most
types of cancer and even several noncancerous conditions. Our
board-certified radiation oncologists are specifically trained to consult,
recommend and oversee all aspects of radiation therapy treatment,
whether alone or in combination with surgery and/or chemotherapy.

Interventional oncology is the use of image-guided, minimally
invasive techniques by fellowship-trained, board-certified interventional
radiologists. Interventional oncology approaches can be used in
conjunction with surgery or with patients who are not candidates
for surgery.

The Varian TrueBeam® Radiation System is part of our
state-of-the-art care:

Our interventional radiologists perform minimally invasive oncology
procedures such as the following:

•

•

•
•

•

•

•

We use a fully integrated system for image-guided radiotherapy (IGRT)
and radiosurgery.
TrueBeam treats cancer wherever radiation treatment is necessary, 		
including lung, breast, prostate and head and neck.
IGRT takes an X-ray before each radiation treatment. The images help
the radiation oncologist to more precisely target existing cancers
while sparing nearby healthy tissue from potential damage and
reducing the risk of side effects.
Intensity-modulated radiation therapy (IMRT) is a procedure that
uses linear accelerators to safely and painlessly deliver precise
radiation doses to a tumor while minimizing the dose to surrounding
normal tissue.
RapidArc is an advanced form of IMRT that uses software and an 		
advanced linear accelerator to deliver IMRT treatments up to eight 		
times faster than was previously possible.
3D conformal radiation therapy, which sculpts radiation beams to
the shape of a tumor, provides a more precise delivery of radiation
designed to avoid healthy surrounding tissues and organs.

Other forms of radiation therapies:
•

•
•

Cyberknife® Robotic Radiosurgery System is a noninvasive treatment
option for tumors anywhere in the body that delivers beams of		
high-dose radiation to tumors with extreme accuracy.
Accelerated partial breast brachtherapy, which treats cancer with
radioactive implants carefully placed into the tissue.
Intraoperative Radiation Therapy (IORT) delivers a concentrated dose
of radiation to the tumor site during surgery, immediately after a
cancer tumor has been removed.

•

•
•

•
•

Radiofrequency ablation (RFA) is a nonsurgical, localized treatment that
is easier on the patient than other therapies. It kills tumor cells with heat
while sparing healthy tissues.
Chemoembolization is a minimally invasive treatment for liver cancer
that can be used when there is too much tumor mass to treat with
RFA, when the tumor is in a location that cannot be treated with RFA,
or in combination with RFA or other treatments.
Cryoablation is similar to RFA, but uses an extremely cold gas instead
of heat to kill the tumor.
Yttrium-90 radioembolization uses radioactive microspheres to treat
both primary liver tumors and metastatic ones that have spread to the
liver by delivering the isotopes directly to the tumor.
Microwave ablation uses heat-generating electromagnectic waves to
destroy tumors.
NanoKnife uses electrical currents to destroy cancerous tumor cells.

Together with the other cancer team members, we provide the most
advanced, minimally invasive approaches to cancer treatment available.
Most interventional procedures are either outpatient or require an
overnight stay in the hospital with a brief recovery time.
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Aurora Cancer Care Spanish Clinic

WHEN YOU NEED THE BEST CANCER CARE, WE'RE
SPEAKING YOUR LANGUAGE.
The Aurora Cancer Care Spanish Clinic is the first — and only — fully
bilingual, Spanish-speaking cancer clinic in Wisconsin. Dr. Federico Sanchez
and his staff provide exceptional care in the management of cancer and
other serious hematologic diseases, while also meeting the language and
cultural needs of patients and their families.
The diagnosis of cancer crosses all cultures and is often life changing.
Patients may feel overwhelmed at first and have many questions. At Aurora
Health Care, we know how important it is to have effective communication
with the care team. Because the more a patient understands their condition,
the less anxiety they will have while treating it.
Federico Sanchez, MD, is the visionary leader behind the Aurora Cancer
Care Spanish Clinic. As medical director of this groundbreaking clinic, he
ushers in a new era of meeting the linguistic and cultural needs of the
growing Hispanic populations in Milwaukee and surrounding area.

CUANDO USTED NECESITA LA MEJOR
ATENCIÓN PARA EL CÁNCER, NOSOTROS
HABLAMOS EN SU IDIOMA.
La Clínica Hispana para la Atención al Cáncer de Aurora es la primera y
única clínica totalmente bilingüe, para la atención al cáncer en Wisconsin.
Nuestro médico y su personal proporcionan atencion especializada para el
manejo del cáncer y otras enfermedades hematológicas graves, a la vez que
satisfacen las necesidades lingüísticas y culturales de pacientes y
sus familias.
El impacto de un diagnóstico de cáncer es similar en todas las culturas y
con frecuencia representa un cambio de vida. Pacientes pueden sentirse
abrumado(a) al principio, y tener muchas preguntas. En Aurora Health Care,
sabemos lo importante que es tener una comunicación eficaz con el equipo
de atención médica. Porque mientras mas entienda su enfermedad, menos
ansiedad sentirá al tratarla.
El Dr. Federico Sánchez es el líder visionario detrás de la Clínica Hispana
para la Atención al Cáncer de Aurora (Aurora Cancer Care Spanish Clinic).
Como director medico de esta innovadora clínica, él encabeza los cambios
hacia una nueva era en la atención medica enfocandose en las necesidades
lingüísticas y culturales de las crecientes poblaciones hispanas en
Milwaukee y sus alrededores.
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Survivorship
For every newly diagnosed cancer case, there are approximately eight survivors living with a history of the disease. After treatment, survivors are
excited about the idea of returning to a “normal” life, but cancer survivors often experience physical, social, emotional, financial, and spiritual changes
as a direct result of their cancer diagnosis and treatment. Survivorship care is gaining prominence as a specialized field, with increased attention and
recognition that care does not end with the completion of treatment but must be extended to include the survivors' long-term health needs.
As part of our comprehensive cancer program, Aurora Cancer Care is utilizing its many resources to develop comprehensive survivorship care.
A survivorship care plan includes a treatment summary as well as a guide to recommended follow-up care and important information about possible
signs of cancer recurrence. We also partner with survivors to design a personalized wellness plan to help them feel better and to stay as healthy as
possible. Survivorship care can also improve coordination between the cancer care team and a patient’s primary care provider. As appropriate, we
can also provide information on integrative medicine strategies to improve wellbeing and genetic counseling to help identify high-risk individuals and
families who could benefit from more comprehensive cancer surveillance.
Survivorship care at Aurora is led by our oncology advanced practice providers and is in alignment with the Commission on Cancer’s accreditation
standards. The program continues to grow; in 2015, when the program was launched, over 600 care plans were distributed. In 2016, 1,100 care plans
were created and/or given to patients and in 2017, 1,252 care plans were completed and delivered to patients.

RESEARCH HIGHLIGHT
WELLNESS COACHING APP
Thanks to a $25,000 Aurora Cancer Care Research Award, Jamie Cairo,
DNP, is studying the immediate and long-term benefits of a wellness
coaching app used by survivors of breast cancer. Researchers will follow
participating survivors for six months to determine whether wellness
coaching provided through the app improved their outcomes. The goals
are to reduce the late and long term side effects of cancer and its treatment,
improve overall quality of life and encourage the adoption of healthy lifestyle
behaviors. The Vida Wellness App study is being conducted by a group of
Oncology Advanced Practice Providers at Aurora Cancer Care. The primary
goal is to examine if use of the Vida Wellness Coach App by breast cancer
survivors is more effective than a self-guided toolkit in improving adherence
to a plant based diet, increasing daily/weekly physical activity, assisting with
a reduction in BMI, reducing elevated baseline post treatment depression
and fatigue scores, and leading to sustained adherence to lifestyle and
wellness plan.
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TEAM PHOENIX SURVIVORSHIP TRIATHLON TRAINING TEAM
Each year, 20-60 women, cancer survivors, some of whom were and are still
going through cancer treatment decide to do a sprint distance triathlon by
joining Team Phoenix.

program is really found in the change they discover in themselves. They
become athletes, they become stronger, they are proud, they are alive, and
they know that they have redefined themselves and their survivorship.

Team Phoenix is Aurora Health Care’s cancer survivor triathlon training team
designed to empower women to take control of their health and redefine
their survivorship by regaining physical fitness, endurance, strength and
flexibility through training for a sprint distance triathlon. Swimming, biking,
running, and, in some cases, fitness in general were brand new to many of
these women.

As one 2017 athlete puts it; “I never thought I could overcome what a
disease had taken from me — my youth, my vitality, my womanhood…This
journey — learning to swim, remembering to run, getting on a bike again...
all small steps that opened the flood gates and let my grief out…I never
thought I would be whole again...and here I am. I am whole…I am back.”

The Team Phoenix program teaches athletes the endurance, technical skills
and knowledge needed to complete a triathlon. However, the impact of the

Since 2011, over 200 athletes have participated in Team Phoenix and most
of those athletes continue to meet or exceed the American Cancer Society’s
Activity Guidelines for regular fitness activities of 150 minutes per week.
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Marija Bjegovich-Weidman Excellence Award in Oncology

Cancer care requires a team effort. In addition to the multidisciplinary approach cancer caregivers provide, Aurora Cancer Care
works with various departments throughout the organization to continue to improve timeliness of care, quality of care, and provide
the best in patient-centered care.
To highlight these collaborations the annual Marija Bjegovich-Weidman Excellence Awards in Oncology were created in 2017 by
James L. Weese, MD to recognize caregivers for their outstanding service and contributions. Multidisciplinary group project
nominations are encouraged to include collaborations between cancer services and other departments within Aurora Health Care.
The awards were named the Marija Bjegovich-Weidman Awards for Excellence in Oncology in honor of Marija who served as Senior
Director of Aurora Cancer Care. Marija has been with Aurora Health Care for over 35 years and has been a driving force behind
Aurora Cancer Care’s success.
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THE 2017 WINNERS INCLUDE:
PERFORMANCE IMPROVEMENT PROJECT AWARD
Anne Weers; Dorry Mitchell; Zarina Dwoodbhai; Rita Wilbert and
Kevin Clement for their work on Improving Referral Capture and
Tracking Outcomes of Lung CT Program
PATIENT OR CAREGIVER SAFETY INITIATIVE AWARD
Brenda Mauer; Kerry Twite, Service Line CNS; Peter Stuessy,
Service Line Pharmacist for their work on Rate/Time Infusion
Process Change for Oxaliplatin
PATIENT-CENTERED PROGRAM OR SERVICE AWARD
Ana Farnsworth, RN, BSN, OCN; Angie Paradowski, CTR; Traci
Batcher; Jennifer Wiesmueller, RN for the work on
The Development of the Sarcoma Multidisciplinary Clinic
INDIVIDUAL LEADERSHIP AWARD
Kerry Twite, CNS for her work in Oncology Nursing Education
The winners, as well as all nominees, were recognized by Dr. Weese,
Vice President of Cancer Services and Dr. Nick Turkal, President
and CEO of Aurora Health Care during the Annual All Oncology
Meeting on Monday, September 18, 2017.
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PREVENTION,
SCREENING & EARLY
DETECTION
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Reaching Out to the Community
Aurora Cancer Care is dedicated to bringing cancer care to
diverse communities. By offering and promoting
cancer education about prevention and screenings, we
provide the community the opportunity to prevent or treat
cancer through early detection. With our resources, we also
give community members evidence based reasons to
become a health advocate for themselves and their loved
ones. Additionally, by being present in diverse community
events and outlets, Aurora Cancer Care has fostered the
visibility as a consistent resource for education and care.
Creating awareness about the importance of screening for
at-risk diseases is the first step in early detection. Our
cancer experts partner with community organizations such
as American Cancer Society, Milwaukee Public Schools, and
the Wisconsin Ovarian Cancer Alliance, Wisconsin Breast
Cancer Coalition, Milwaukee Consortium for Hmong Health,
Wisconsin LGBT Chamber of Commerce. Together we
conduct community outreach through various community
events to provide education, conduct presentations and
discussions, distribute brochures and materials, and provide
cancer screenings to participants in these events and
health fairs. Additionally, our cancer experts also serve as
volunteers on various boards of directors for community
based organizations.
Early detection of cancer has immeasurable benefits to the
patient and their families. Many times, detection of cancer
in the early stages, as opposed to a late stage, means better
prognosis, higher cure rates, lower costs of treatment and
health care, less impact on quality of life, and less time away
from work.
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BY THE
NUMBERS
Early vs. Late-Stage Cancer

PROGRAMS FOR EMPLOYERS AND EMPLOYEES

Treatment Costs

ON-SITE SCREENING
Late-Stage

Early-Stage

Our experts come to your place of work to conduct several
types of screenings.

$180,000

•
$160,000

•
$120,000

Cost

•

Breast and oral screenings: conducted in private and include education
about ongoing self-exams, as well as risk factors and signs and
symptoms to watch out for.
Colorectal screenings: employees collect a sample from the comfort
of their own homes, return as instructed and are then contacted with
results and next steps.
Skin screenings: conducted in private to examine skin lesions and
include education about ongoing self-exams, as well as risk factors
and signs and symptoms to watch out for.

$80,000

EDUCATIONAL PRESENTATIONS AND MATERIALS
Creating awareness about the importance of screening for at-risk diseases is
the first step in early detection. Our cancer experts come on-site to provide
education, conduct presentations through the Aurora Cancer Care Speaker’s
Bureau, and distribute brochures and other materials to increase awareness.

$40,000

0

Lung

Colorectal

Breast

Type
Source: Milliman, Inc. et al, Comparing Episode of Cancer Care Costs in
Different settings: An Actuarial Analysis of Patients Receiving Chemotherapy,
Aug 29, 2013
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RESEARCH
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In August 2014, the National Cancer Institute (NCI) chose Aurora Health
Care as a community site for its newly instituted NCI Community
Oncology Research Program, or NCORP. Aurora is projected to receive
more than $4.4 million by the time its five-year NCORP grant cycle ends
in 2019. Thomas Saphner, MD, and Michael Thompson, MD, PhD, serve as
principal investigators for Aurora NCORP. Along with their team members,
the principal investigators authored a paper in the Wisconsin Medical
Journal about establishing a new NCORP site.
Aurora is one of 34 sites in the country to be awarded one of the
highly competitive NCORP grants, which help bring clinical cancer
trials to people in their own communities. This expanded access to
clinical trials, in turn, generates more broadly applicable evidence that
contributes to improved patient outcomes and a reduction in cancer
disparities. The NCORP grant stimulates interactions with in the oncology
community including, medical, surgical, gynecologic, and radiation
oncology. Interactions between the oncology community and several
other specialties are enhanced including, cardiology, behavioral health,
complementary medicine, geriatric medicine, diagnostic radiology, and
medical genetics.
Currently, Aurora NCORP has NCI clinical trials open to recruitment for
multiple cancer types, including brain, breast, lung, and prostate cancers,
as well as leukemia, lymphoma, and melanoma. These clinical trials are
available at all 19 Aurora cancer clinics.

The NCI chose Aurora to serve as a community site
because we are the largest cancer provider in
Wisconsin — diagnosing and treating more adult
cancer than any other health care system in the state.
Beyond that, Aurora’s work in a variety of clinical research areas,
including multidisciplinary studies in neuro- and cardio-oncology,
makes us especially attractive as a community site. NCORP includes
a range of cancer prevention, screening, control and treatment
clinical trials.

BY THE
NUMBERS
181 oncology clinical trials
open to accrual and follow-up
as of

Dec. 31, 2016

Gynecology
(26) 14%
Hematology
(24) 13%
Other
(36) 20%

Lung
(15) 8%
Prostate
(13) 7%

Breast
(49) 27%

Colorectal
(12) 7%
Renal Cell
(6) 3%
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NCORP PHYSICIAN ACCRUAL AWARD WINNERS
AUGUST 2014 - JUNE 2017

At the National Cancer Institute NCORP meeting in August of 2017,
the NCI recognized investigating physicians for excellence in accrual
of patients to clinical trials. Total accrual to NCI sponsored trials was
totaled for the first three years of the NCORP grant and investigators
with more than 11 accruals were recognized.
Only about 10% of all investigating physicians in all NCORP sites
were recognized. Aurora was honored to have 13 investigating
physicians recognized.

PLATINUM AWARD WINNER: Dr. Shamsuddin Virani (>50)
GOLD AWARD WINNER: Dr. Michael Mullane (40)

Two research organizations recently

APPRECIATION AWARDS: (11-19)

recognized Aurora for its exemplary

- Dr. Corey Shamah (19)
- Dr. Judy Tjoe (17)
- Dr. George Bobustuc (16)
- Dr. Rubina Qamar (16)
- Dr. Dhimant Patel (15)
- Dr. Gilberto Rodrigues (15)
- Dr. John Maul (13)
- Dr. Ubaid Nawaz (12)
- Dr. Osama Halaweh (12)
- Dr. Cheruppolil Santosh-Kumar (12)
- Dr. Thomas Saphner (12)
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work enrolling patients in clinical trials.
•

NRG Oncology recognized Aurora as a top five		
accruing NCORP site

•

The Alliance for Clinical Trials in Oncology			
recognized Aurora as one of its top 50 highest		

RESEARCH HIGHLIGHT
EARLY PHASE CANCER RESEARCH PROGRAM
Early phase (Phase I, I/II, II) clinical trials lay the foundation for later
trials powered with more participants to determine whether a drug is
safe and effective. Michael Thompson, MD, PhD, director of the Early
Phase Cancer Research Program at Aurora Research Institute, believes
early phase trials play an even more critical role in cancer care.
According to a statement from the American Society of Clinical
Oncology (ASCO) co-authored by Dr. Thompson in January 2015,
new targeted molecular therapies and immunotherapies have
provided promising results in early stage trials. Also, innovative early
phase trial designs that match participants with treatments based on
genetic biomarkers have allowed researchers to better identify
populations that may benefit from these newer drugs.
Most early phase studies are designed with therapeutic intent.
Phase I trials are statistically powered to evaluate safety while Phase II
trials assess how well investigational treatments work (efficacy)
before they can be tested against the current standard of care
(Phase III trials). Because of the concerted effort at Aurora Health
Care to offer more early phase clinical trials, more participants are
receiving the latest options in the fight against cancer.

No. of Early Phase Clinical Trials
2009 - 2016
0

2

4

6

8
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12

14

2009
2010
2011
2012
2013
2014
2015
2016

The program launched in 2013, and in 2016, Aurora’s Early Phase
Cancer Research Program reached a milestone with 14 early phase
cancer clinical trials available, the most Aurora has offered.
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BLOOD & BONE
MARROW CANCERS
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Cells in blood develop from the bone marrow, the spongy material
in the center of the bones. Stem cells divide and turn into
different kinds of cells — white blood cells, red blood cells, platelets,
etc. These cells have a finite lifespan and new cells take the place of
dying cells. The bone marrow is constantly regenerating. However,
there are times when this process goes wrong and cells do not grow
or divide normally and develop into cancers. Cancer of these cells
include leukemia, multiple myeloma, and lymphoma.

LEUKEMIA
In a person with leukemia, the white cells are generated in large
numbers and overcrowd the other normal white blood cells, red blood
cells and platelet cells, inhibiting these cells from doing their normal
work. Leukemia can be described as fast growing (acute) or slow
growing (chronic) and is further classified by type of blood cell
affected (lymphoid or myeloid). There are multiple types of acute
leukemia whereas chronic leukemia belongs mostly to two different
types, myeloid and lymphatic.

MULTIPLE MYELOMA
Multiple myeloma is the overproduction of plasma cells, a type of
lymphoid cell in the bone marrow. These abnormal plasma cells can
coalesce and form tumors.

LYMPHOMA
Lymphoma is cancer in the lymphatic system of the body.
Lymphocytes are a subset of white blood cells used to protect our
bodies from germs. They are intimately involved in immune function.
Hodgkin’s and Non-Hodgkin’s lymphoma are the two most common
types of lymphomas.

BY THE
NUMBERS
Patients Diagnosed at Aurora
2016

Leukemia
279

BLOOD & BONE
MARROW

467

Multiple
Myeloma
92
Other
96
Hodgkin's
Disease
38

LYMPHATIC
SYSTEM
Non-Hodgkin's

.

336

298
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Aurora Cancer Care has been accredited by the Foundation for the
Accreditation of Cellular Therapies for over 20 years and counting.

Our Aurora Health Care Autologous Stem Cell Transplant Program has been re-accredited by the Foundation
for the Accreditation of Cellular Therapy (FACT). This accreditation applies to all services and facilities that are
inspected by FACT, specifically adult autologous hematopoietic progenitor cell transplantation, peripheral blood
cellular therapy product collection, and cellular therapy product processing with minimal manipulation.
The clinical, peripheral blood collection and processing facilities located at Aurora St. Luke’s Medical Center in
Milwaukee were also part of the inspection and successful re-accreditation process. Achieving FACT
re-accreditation reflects our ongoing commitment to exceeding standards in patient care and laboratory
practices for patients receiving cellular therapy.
Our program has a long history of commitment to excellent patient care and outcomes. Our program was
launched in 1991 and has transplanted 724 patients as of the third quarter of 2017.
Treatment for blood and bone marrow cancers includes chemotherapy, immunotherapy, radiation therapy, and stem cell
transplantation. Chemotherapy is the use of potent drugs or chemicals that are used to kill and/or damage the cancer cells.
Chemotherapy is usually given in cycles and with some treatments may need to be given in a hospital. There are multiple
targeted therapies and immune therapies used in treatment of leukemia, lymphomas, and myelomas.
The Malignant Hematology Case Conference to discuss patient care started late September 2017 and takes place twice
a month. In the first three conferences held, 15 cases have been discussed.
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MELANOMA &
MUSCULOSKELETAL
CANCERS
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BY THE
NUMBERS
Musculoskeletal cancer is any cancer that develops in bone or soft
tissue, such as muscle. This can include bone cancer (bone
sarcoma), soft tissue sarcoma and bone cancer that has spread
from other parts of the body (metastatic carcinoma).

Patients Diagnosed at Aurora
2016

Skin cancer (also referred to as melanoma) is a tumor or growth of
abnormal cells on the skin, the body’s largest organ. These skin
tumors can be benign (noncancerous) or malignant (cancerous).
There are three types of skin cancer:
•
•
•

Basal cell carcinoma is the most common type. It typically		
occurs on the surface layer of skin.
Squamous cell carcinoma is the second most common		
type and it also develops on the outer layers of skin.
Malignant melanoma is the most serious type, since it’s more
likely to spread beneath the skin. It can be life threatening:
10,000 people will die this year from melanoma.

Although skin cancer is the most common form of cancer, skin has
an incredible capacity to heal and regenerate. Skin cancer is
often treatable, especially if caught early.
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Nov-Dec
Aurora Cancer Care's Multidisciplinary Sarcoma

2016

22 Cases Discussed

Clinic is named to the nationally-recognized

Multidisciplinary
Cancer Conferences

Sarcoma Alliance
Aurora Cancer Care has been recognized as a national resource for patients and their
families by the Sarcoma Alliance, an organization dedicated to guidance, education, and
support for people with the rare condition. It is important to find physicians who have
experience with the disease and the Sarcoma Alliance requires providers to meet specific
criteria to qualify as a recognized clinic.

Jan-Dec

2017

166 Cases Discussed

Nicholas Webber, MD, Medical Director of Sarcoma Services and Orthopedic Oncology,
and the entire sarcoma team work tirelessly to provide the best care options available to
patients across the country. The multidisciplinary team participates in weekly conferences
to discuss cases with other sarcoma experts from around the globe.

RESEARCH HIGHLIGHT
Nov-Dec
EXPLORING IMMUNOTHERAPIES FOR ADVANCED MELANOMA
Monoclonal antibodies that trigger the immune system, such as ipilimumab and
nivolumab, may stimulate white blood cells to kill the tumor cells.
Manish Pant, MD is the local principal investigator of a Phase II/III clinical
trial exploring whether nivolumab and ipilimumab are more effective with
sargramostim, which stimulates white blood cell production, in the treatment
of patients with Stage 3 or 4 melanoma that cannot be removed by surgery
(clinicaltrials.gov identifier: NCT02339571). The study is sponsored
by ECOG-ACRIN in collaboration with National Cancer Institute.

Multidisciplinary
Clinic Visits

2016
22 Visits

Jan-Dec

2017
150 Visits
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Global Multidisciplinary Sarcoma Video Conference
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GYNECOLOGIC
CANCERS

38

BY THE
NUMBERS
Aurora Health Care strives to see each woman who has been
diagnosed with gynecologic cancer not as her disease, but as the
person she was before diagnosis. We work to treat the whole person,
not just the cancer.
Gynecologic cancers involve the female reproductive organs, which
include the uterus, ovaries, cervix, fallopian tubes, vagina, and vulva.
The American cancer society predicted that in 2017 over 107,000 new
cases of female gynecologic cancers will have been diagnosed, and over
31,000 women will have died of these diseases. Any female is
unfortunately at risk of developing one of these cancers. Regular
physical exams, as well as diet, exercise, and lifestyle choices, play
a role in not only the prevention of these cancers, but also in detecting
them early. Education as to the signs and symptoms of each of these
cancers is vital for women to understand when they should go the
doctor to be evaluated.

Patients Diagnosed at Aurora
2016

FEMALE
GENITAL

577
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Endometrial cancer, or uterine cancer, is the most common gynecologic
cancer, and the fourth most common cause of cancer in women. Endometrial
cancer is sadly one of the cancers that is actually increasing in incidence in
the country, rather than decreasing. The reason for this is that many uterine
cancers are linked to obesity, and the obesity epidemic is on the rise.
Uterine cancer, however, does have a very significant symptom:
post-menopausal bleeding. Any bleeding after menopause should be
evaluated by a primary physician or a gynecologist.
Ovarian cancer (including primary peritoneal and fallopian tube cancers),
while less frequent than uterine cancer, is deadlier. It is the fifth most
common cause of cancer death in women, over 14,000 women will die of
ovarian cancer in 2017. The main reason that it is so deadly is that unlike
uterine cancer, which can be caught very early, ovarian cancer is typically
not caught until later stages of disease. The reason is there is no approved
screening tool for ovarian cancer, and the symptoms are very similar to
concerns women have commonly (bloating, fatigue, bowel and bladder
changes, weight changes). While we still search for a screening tool, it is
important for women to listen to their bodies and go see their physician if
they are having changes in symptoms or any concerning signs.
Cervical cancer is the one gynecologic cancer that has a known and
effective screening tool: the Pap smear, and more recently, HPV testing.
The majority of cervix cancer is caused by HPV, which changes cells and
causes them to grow without regulation, which in turn become cancer.
Screening guidelines have changed over the years, so it is good to talk with
your physician about when to have a Pap smear and HPV screening test.
HPV vaccination is also becoming more and more mainstream and could
potentially decrease cervical cancer rates dramatically by stopping the
major cause of cervical cancer.
Vulvar and vaginal carcinoma are less frequent, but still extremely important
to be aware of. Many of these cancers are caused by HPV as well. As women
get older, these cancers are more common, and many women are unaware
of what to look for (itching, burning, redness, sores or ulcers). Many of these
symptoms are very similar to having other concerns (urinary tract infections,
vulvar skin conditions such as lichen sclerosis), but it is very important that if
any of the symptoms change, women have an exam. It is also harder to look
“down there” as we get older, and having your physician look in the genital
area once a year will help to catch any concerning condition early.
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COMMUNITY PARTNERS
In 2017, Wisconsin Ovarian Cancer Alliance (WOCA) in partnership with
Aurora Health Care, was awarded a grant from the Ovarian Cancer Research
Fund Alliance (OCRFA) for the Woman to Woman program. This unique
program pairs newly diagnosed gynecologic cancer patients with survivor
volunteers to provide one on one emotional support and mentoring;
essentially a “buddy” system.

LEADER IN INNOVATIVE TREATMENT IN WISCONSIN
Aurora hospitals have the leading robotics program in the state for women receiving robotics surgery since 2007. The robotics programs not only
provide the most robotics surgery for women in the state of Wisconsin, but also allow patients to receive their robotics staging surgery for cancer and go
home the very same day.
This innovation has revolutionized the surgery for uterine cancer staging, changing the operation from having a large incision and staying days to weeks in
the hospital, to having five tiny incisions, and going home the same day or the next day. Quicker recovery allows patients to move on to the next phase of
their cancer treatment that much faster.
Minimally invasive surgery has transformed patients' surgical experience, allowing them to have surgery for their cancer with minimal discomfort, shorter
hospital stays, and fewer complications. Especially for endometrial cancers, minimally invasive and robotics surgery has become the forefront of standard of
care for surgical staging.
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GENITOURINARY
CANCERS
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BLADDER CANCER
Bladder cancer is the most common form of urinary tract cancer.
Symptoms may include blood in the urine (urine may be orange,
pink or red), changes in urination frequency, pain or burning
during urination, and back or abdominal pain. Early detection
and treatment often yield positive long-term results.
PROSTATE CANCER
Cancer of the prostate occurs very commonly in men with over
220,000 new cases in the United States every year. About 30,000
men in the United States die of prostate cancer every year. Some
prostate cancers are slow-growing and do not cause harm, but
other forms of prostate cancer can be aggressive and cause death.
For men aged 55 to 69 years, the decision to undergo
periodic prostate-specific antigen (PSA)–based screening for
prostate cancer should be an individual one. Before deciding
whether to be screened, men should have an opportunity to discuss
the potential benefits and harms of screening with their clinician
and to incorporate their values and preferences in the decision.
Shared decision making is the best approach in determining
appropriate PSA based screening for prostate cancer.

BY THE
NUMBERS
Patients Diagnosed at Aurora
2016
Prostate
921
Testis
38

MALE GENITAL

966

Other
7

TESTICULAR CANCER
Testicular cancer is not common; according to the American Cancer
Society, about one of every 263 males will develop testicular cancer
at some point during their lifetime. The average age at the time of
diagnosis of testicular cancer is about 33. This is largely a disease
of young and middle-aged men, but about 7% of cases occur in
children and teens, and about 7% occur in men over the age of 55.
Because testicular cancer usually can be treated successfully, a
man’s lifetime risk of dying from this cancer is very low: about one
in 5,000.

Bladder
394
Kidney/Renal
284

URINARY SYSTEM

Other
23

701
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KIDNEY CANCER
Kidney cancer is one of the top ten most common cancers in men and women. Each year, more than 60,000 Americans are diagnosed		
with kidney cancer. It’s more common in men, especially those in their 50s to 70s who are or were smokers.
There are four different types of kidney cancer:
•

•
•
•

Renal cell carcinoma (RCC): This is the most common form of adult kidney cancer (about 85% of cases). RCC usually starts as a single tumor
in one kidney, but it can affect both your kidneys and spread (metastasize) to other organs. It begins in the cells that line the small tubes that
are part of the nephrons within your kidneys.
Transitional cell carcinoma: This form of kidney cancer usually begins in the area where a ureter connects to the main part of a kidney (called
the renal pelvis). This cancer represents 6% to 7% of all kidney cancers and can also grow in your ureters or bladder.
Renal sarcoma: The least common form of kidney cancer (1% of cases), renal sarcoma begins in the connective tissues of your kidney. If left
untreated, it can spread to nearby organs and bones.
Wilms’ tumor: The most common type of kidney cancer in children, it accounts for approximately 5% of total patients with kidney cancer.

MINIMALLY-INVASIVE TECHNIQUES
Many genitourinary cancers can now be treated through various minimally-invasive techniques.
Laparoscopic Partial Nephrectomy provides patients with a safe and effective way to remove a small renal tumor, while preserving the remainder
of the kidney. This is a minimally invasive technique, which provides patients with less discomfort and equivalent results when compared to the
traditional open surgery.
Greater than 95% of patients who are treated by the Aurora Cancer Care Urology team receive a partial nephrectomy for those kidney tumors
</= 4cm in size.
For years, surgeons removed cancerous cysts in the bladder with an open surgical procedure called a cystectomy. In some cases, this type of
procedure led to post-operative complications. Today, minimally invasive surgical options like robotic-assisted cystectomy offer less pain, shorter
recovery times, and better outcomes.
The main type of surgery for prostate cancer is a radical prostatectomy. Robotic assisted prostatectomy is commonly used and is one way of
doing this surgery for prostate cancer. It’s a minimally invasive surgical procedure and has advantages over the open approach in terms of less
pain, blood loss and recovery time.
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RESEARCH HIGHLIGHT
STUDY EXPLORES RECURRENCE-FREE SURVIVAL FOLLOWING ROBOTIC PROSTATECTOMY
Decisions regarding prostate cancer treatment options can be difficult for the person facing that diagnosis. For men who have considered
undergoing robotic-assisted laparoscopic radical prostatectomy (RALP), they can be assured that the biochemical recurrence-free
survival (BRFS) outcome they would achieve at Aurora Health Care is better than many recurrence and disease-free survival rates
published by other leading institutions across the United States.
As part of an Aurora Cancer Care quality project, the Aurora Cancer
Registry sponsored a study to determine prostate cancer BRFS rates
following RALP. Post-operative prostate-specific antigen (PSA) values
were obtained, and biochemical recurrence was defined as PSA > 0.2 ng/
mL after 12 months. Danielle Greer, PhD, Aurora biostatistician, reviewed
all analytical prostate cancer cases diagnosed during 2009 to 2011 and
treated with RALP at any of the five Aurora hospitals then equipped to
perform robotic procedures. She computed BRFS rates for up to three
years following cancer diagnosis and used statistical models to examine
variation in the rates, based on well-known prognostic indicators.
Out of the total 500 Aurora patients who underwent RALP, the overall
BRFS rate at three years was 95.7%. Some groups of patients experienced
different levels of recurrence risk. For instance, AJCC stage of disease,
Gleason score and D’Amico risk level all significantly impacted the
relative risk of recurrence and, consequently, led to variable rates of
BRFS. However, overall BRFS rates were exceedingly high, providing
evidence of Aurora’s success in robotic surgery.
Why are our results excellent? Because Aurora Health Care evaluates each
patient with weekly multidisciplinary input by high-volume surgeons,
radiation oncologists, medical oncologists, pathologists, genetic
counselors, and clinical coordinators, and treatment is provided in
accordance with evidence-based guidelines. This methodology is also in
conjunction with our Commission on Cancer accreditation commitment
— to provide outstanding high quality patient-centered care to each and
every person seen.

The genitourinary multidisciplinary clinics

2016.
In that short time, 13 patients

(MDC) began in November

were seen by their care team in the MDC.

Multidisciplinary
Clinic Visits

Nov-Dec

Jan-Dec

2017
78 Visits

2016
13 Visits
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GASTROINTESTINAL
CANCERS
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Aurora Health Care has continued to see more cancer cases than any
other health care system in Wisconsin. We continue to see 20% of all
new GI cancers diagnosed in Wisconsin and have developed several
new programs to meet the needs of our patients. A new gastrointestinal
cancer tumor board was instituted, and, through presentation and
multidisciplinary discussion, we have helped or will help over 700
patients obtain the proper treatment. This meeting which is open to all
Aurora caregivers, meets weekly, and allows for expert consultation for
both common and esoteric GI cancers. Our GI quality committee
continues to review best practices and has made substantial
improvements in the time it takes for patients to receive treatment
after diagnosis. We are also monitoring several quality indicators
which reflect the highest quality of care delivered through our system.

Several cancer physicians throughout the Aurora Health Care system
met during 2016 and 2017 to determine the best practices for patients
with colorectal, anal, pancreas, stomach, esophagus, liver, gall bladder
and bile duct cancers. During these meetings, participants from all of
the disciplines treating these complex cancers came together to agree
on the proper course and sequence of treatments that should be
recommended. These guidelines are disseminated throughout the
system to serve as a guide for the care of complex GI malignancies
and to serve as the benchmark for outstanding cancer care.

Jan-Dec

2016
177 Visits

Patients Diagnosed at Aurora
2016
Esophagus
80

MULTIDISCIPLINARY CANCER CARE

Multidisciplinary
Clinic Visits

BY THE
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Stomach
85
Colon
378
Rectum
144
Anus/
Anal
34
Liver
99

Jan-Dec

2017
133 Visits

Pancreas
179
Other
134

DIGESTIVE SYSTEM
TOTAL

1,133
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NEW INNOVATIVE TREATMENT TECHNOLOGY—HIPEC AND NANOKNIFE®
HIPEC, or Hyperthermic Intraperitoneal Chemotherapy instillation, is a treatment for peritoneal based cancers, and for cancers that recur in the
peritoneal cavity. This technique is used for cancers of the appendix, peritoneum, colon, stomach and gynecologic organs. During this procedure
surgeons remove or debulk the majority of the tumors, and then instill chemotherapy heated to 42°C for 90 minutes. Since the inception of this
program, we have treated 12 patients and have embarked on a research study with Concordia University to determine the absorption of the chemotherapy
both into tissue and systemically.

NANOKNIFE IRREVERSIBLE ELECTROPORATION (IRE) SYSTEM
The NanoKnife Irreversible Electroporation (IRE) System allows us to treat locally advanced and unresectable tumors, predominately in the pancreas and liver.
Aurora is the first and only site in Wisconsin to have this technology, which allows us to treat these traditionally unresectable tumors in situ with preservation
of the vital structures which cannot be removed. By running DC electrical current through the tumors, small holes or pores are created which allow these
cancer cells to die and be absorbed by the body while preserving the normal architecture which surrounds the cancers. In published studies, patients
with unresectable pancreatic cancers have a survival which is doubled after NanoKnife IRE treatment. Three patients (two with pancreas cancer and one
with liver cancer) have been treated thus far.
The Vince Lombardi Cancer Foundation (VLCF) funded the NanoKnife technology at Aurora St. Luke’s Medical Center and we are, as of yet, the only health system
in Wisconsin that can provide this treatment option. The VLCF has provided additional funding to strengthen the NanoKnife program which we hope to use to
expand the program to involve our interventional radiologists and increase access to the technique.

Aaron Chevinsky, MD led a team
We are the

at Aurora St. Luke’s Medical Center

only site in Wisconsin

that became the

to use NanoKnife, and it can be used for

first in the state to use

any tumor that is surgically unresectable

NanoKnife technology on patients with

because of involvement of a blood vessel.

otherwise inoperable pancreatic
and liver cancers.
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RESEARCH HIGHLIGHT
CANCER CARE DELIVERY RESEARCH (CCDR)
CCDR is a new initiative within NCORP. It examines how systems, such as financial structures and survivorship support, affect cancer care delivery. NCI, along
with research bases that are responsible for developing NCORP trials, are working together now to create CCDR studies.
In late 2017, our first accrual to a CCDR trial, S1417 CD Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer, was made by
Fred Sanchez, MD. This trial looks at the financial implications of diagnosis of metastatic colon cancer to a newly diagnosed patient.

DESIGNATED PANCREATIC CANCER TREATMENT CENTER

AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Aurora Health Care was named a designated Pancreatic Cancer Treatment
Center by the National Pancreas Foundation, the first and only one in the state
of Wisconsin. This designation highlights our commitment to clinical excellence,
research, and our multidisciplinary approach to cancer care. All of our
patients are treated by a team dedicated to their physical, emotional and
spiritual well-being. Our Cancer Nurse Navigator program allows for the
seamless transition between medical services and serves to meet our patients
continuing needs before, during, and after treatment.

Among multiple presentations this year given by Aurora clinicians, a
presentation was given at the ASCO GI meeting in San Francisco
demonstrating the outstanding care we have provided for patients
with pancreatic cancer. We are continuing to expand research into
gastrointestinal cancers and will strive to improve the options for our
patients. We are also active in providing continuing medical education
through our various conferences and meetings, and are planning a
CME meeting dedicated to the treatment of pancreatic cancer in 2018.
The future looks promising as we strive to improve our cancer
treatments and incorporate the latest developments in research
and precision medicine into our treatment programs.
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Patients Diagnosed at Aurora
2016

80

Aurora Health Care treats one

Esophagus

out of every four lung cancer
patients in Wisconsin .

877

Lung/
Bronchus

Aurora Health Care treats one out of every four lung cancer patients in
Wisconsin. Our multidisciplinary team brings together a group of dedicated
lung cancer specialists; including thoracic surgeons who specialize in lung
cancer surgery, pulmonologists, medical oncologists, radiation oncologists,
cancer care coordinators, dietitians, cancer rehabilitation specialists, and
Cancer Nurse Navigators to provide personalized care using the latest
treatments and technologies. Our comprehensive program offers
cutting-edge techniques and screenings for patients from all fifty states.
For example, in 2016, Aurora Grafton, Aurora St. Luke’s, and Aurora Summit
medical centers performed 1,029 thoracic surgical procedures.

Jan-Dec

2017
69 Visits

Jan-Dec

Multidisciplinary
Cancer Conferences

Multidisciplinary
Clinic Visits

Jan-Dec

2016
52 Visits

2017
561 Cases
Discussed

Jan-Dec

2016
400 Cases
Discussed

MULTIDISCIPLINARY CANCER CARE
Multidisciplinary Cancer Conferences and Multidisciplinary
Clinic visits are available weekly for patients with thoracic cancers.
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Video-Assisted (VATS) Lobectomies
2011 - 2016
Aurora

STS

%
100.0
97.5

General Thoracic Surgery Volume
2011 - 2016

50.0

0.0

Volume

1,500
1,000

693

756

2011

2012

885

933

1029

2014

2015

2016

2011

2012

2013

2014

2015

2016

Year

647

500
0

2013
Year

The majority of lung cancer surgery (97.5%) performed at Aurora
Grafton, Aurora Summit, and Aurora St. Luke’s in 2016 were
Video-Assisted Procedures (VATS), a minimally invasive technique
that is used when appropriate to yield the best possible outcome for
each patient.
VATS may also be used with a robotic technique. Minimally invasive
surgery has been shown to decrease length of stay as well as postoperative complication rates. Aurora Health Care is able to accommodate the many patients who desire a minimally invasive approach.
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54.0

According to US News and World Report, Aurora received the ‘best’
ranking for survival thirty days after thoracic surgery as well as the
‘best’ ranking for preventing prolonged hospitalizations.

Aurora Health Care is proud to provide a highly qualified and effective
treatment team for our lung cancer patients. For example, Aurora Health
Care’s William Tisol, MD, leads one of the busiest robotic-assisted
thoracic surgery practices in the world. Aurora Medical Center in
Grafton serves as a case observation center for the state of the art
Intuitive Surgical da Vinci XI® surgical system. Surgeons and their teams
come from all over the country to observe robotic assisted thoracic
surgery. Aurora Medical Center at Grafton is one of ten approved
thoracic robotic surgery mentor sites in North America and one of two
in the Midwest hosting over fifty guests per year. Joining our lung cancer
treatment team and our nationally recognized robotic-assisted thoracic
surgery program is. David Demos, MD, from Stanford University Hospital.

Lobectomy Postoperative Length of Stay
2014 - 2016
0
AHC

(Jan 2014-Dec 2016)

4

8

3.7

N=420

STS
(Jan 2014-Dec 2016)

4.0

N=25,696

Pulmonary Resection Mortality

NIS
(Jan 2014-Dec 2016)

2011 - 2016

4.9

N=25,675

Abbreviations:
•
AHC — Aurora Health Care
•
STS — Society of Thoracic Surgery
•
NIS — Nationwide Inpatient Sample — largest		
all-player inpatient care database in USA

%
4.0
2.4
2.0
0.3
0.0
2011
2012
(N=255) (N=223)

2013
(N=211)

2014
2015
2016
(N=283) (N=296) (N=287)

RESEARCH HIGHLIGHT
BLOCKING EFFECT OF A MUTATION IN NON-SMALL CELL LUNG CANCER
In some patients with non-small cell lung cancer the tumor cells have a certain mutation referred to as Epidermal Growth Factor Receptor (EGFR).
The EGFR is a receptor molecule on the surface of some lung cancer cells. The approved chemotherapy drug afatinib is the first-line treatment for
patients with EGFR-positive non-small cell lung cancer. Afatinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. In a Phase II/III clinical trial led by Dhimant Patel, MD, researchers are studying whether afatinib plus cetuximab, a monoclonal antibody
that triggers the immune system, may be more effective in blocking tumor growth versus afatinib alone in this population (clinicaltrials.gov identifier:
NCT02438722). The study is sponsored by SWOG in collaboration with National Cancer Institute.
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PREVENTIVE CARE
The best time to fight breast cancer is before it even begins. Aurora
uses genetic testing, mammograms, breast imaging, and breast MRI to
help low and high-risk individuals harness the power of preventive care.
Because the best fight against breast cancer is the one that never has a
chance to get started.

In 2016,

1,301 Aurora patients

were diagnosed with breast cancer

PERSONALIZED CARE
When a patient receives a breast cancer diagnosis, they are never
alone. We make sure the answers and support needed is met with a
personal cancer nurse navigator — a specially trained registered nurse
who provides support, coordinates care, and answers all questions
and concerns.

ACCREDITED CARE
Many of our breast care centers are accredited by the National
Accreditation Program of Breast Centers (NAPBC). This means our
centers have met or exceeded quality standards established by the
NAPBC, an organization committed to the highest measure of care
for patients throughout all breast cancer stages.

“Different guidelines have been put forth by different organizations and
physician societies,” explained William Owens, MD, a breast surgeon at
Aurora BayCare Medical Center and the subcommittee’s chair. “We want
to make sure clinicians are aware that breast health specialists have
considered the guidelines and it is our recommendation that they use
the American Cancer Society guidelines.”
The subcommittee has developed:
•
•
•
•

Screening strategies for average, intermediate, and high risk patients
Criteria to refer patients for genetic evaluation
Guidelines for standardizing care for sentinel lymph node resection
Post-Lumpectomy Screening guidelines

MULTIDISCIPLINARY CANCER CONFERENCE

BREAST CANCER QUALITY SUBCOMMITTEE
Aurora Cancer Care has formed a system-wide Breast Cancer Quality
Subcommittee — comprising 31 clinicians in primary care, oncology,
radiology, and breast surgery — to establish uniform guidelines across
the system for breast cancer screening and treatment using
evidence-based, national guidelines.

All breast cancer patients newly diagnosed with breast cancer are
presented at a multidisciplinary conference. While these meetings will
be held regionally, all Aurora sites that care for breast cancer patients
will be able to participate by video conferencing. Various Aurora Cancer
Care locations will be partnered with one of these conferences based on
the site’s volume, patient flow, and meeting times.
These conferences give providers the opportunity to discuss the patient
diagnosis, medical management, and discuss evidence-based practices
to provide care with the best outcomes for patients.
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Effective Radiation in Fewer Treatments
RADIATION TREATMENT
As the cost of health care delivery continues to increase, it is prudent to deliver the best evidence-based care at the lowest-possible cost.
Breast cancer — the most frequently diagnosed cancer globally and leading cause of cancer death in women — has seen a great evolution in
care over the last 40 years. For those patients diagnosed with an early stage breast cancer, breast-conserving therapy is a common
treatment recommendation, which pairs a partial mastectomy with adjuvant radiation therapy. In multiple randomized trials, adjuvant
radiation therapy has been proven to decrease local recurrences and improve overall survival. Traditionally, conventionally-fractionated dose
schedules have been employed to deliver therapy daily over a period of five to six-and-a-half weeks, whereas hypofractionated therapy can
be delivered over a period of three to four weeks. Recent data has demonstrated equivalent tumor control and cosmetic outcome in specific
populations with shorter courses of radiation therapy, which is delivered in a hypofractionated manner over approximately four weeks.
Hypofractionated regimens deliver more radiation therapy per dose, enabling fewer total treatment fractions per course.
In 2011, a white paper was published in the International Journal of Radiation Oncology, Biology, Physics entitled “Fractionation for Whole
Breast Irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline.” A systematic review of the literature
was conducted, analyzing nine randomized trials comparing hypofractionated RT to conventionally fractionated RT or partial breast
irradiation. In addition, 34 nonrandomized clinical studies were analyzed. Evidence from these trials demonstrated that hypofractionated
radiation and conventionally fractionated radiation therapy were equally effective in terms of breast tumor control. Additionally,
cosmesis and long-term toxicities were similar regardless of fractionation schedule.
ASTRO defines the following criteria for those thought to be appropriate for hypofractionated technique:
Patient is 50 years or older at diagnosis.
Patient has pathologic stage T1/2 N0 and underwent breast-conserving therapy.
Patient did not receive systemic chemotherapy.
ASTRO notes, however, that women with larger breasts may not be eligible for hypofractionation.
At Aurora Cancer Care, we evaluated the patients deemed eligible for hypofractionated radiation therapy to determine whether they were
offered this option and, if offered, whether treatment was delivered in this fashion. Individual radiation oncologist data were reviewed and
discussed with each on a one-on-one basis. The resulting outcome of practice reflects an increase in discussion and implementation of a
hypofractionated treatment plan for eligible women with breast cancer.
As we move toward value-based care, it is encouraging to see that evidence-based information was used to reduce the number of
treatments given to appropriately selected patients, which can improve patient satisfaction and reduce cost in the process.
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RESEARCH HIGHLIGHT
TORQUE Transitional Oncology Research: Quest for Understanding & Exploration
According to the American Cancer Society, there are more than 3.1 million breast cancer
survivors in the United States, including women still being treated and those who have
completed treatment.
Surgeon Judy A. Tjoe, MD, FACS, aims to change the face of breast cancer care and
survivorship through Aurora Research Institute’s breast cancer research program,
Translational Oncology Research: Quest for Understanding & Exploration, or TORQUE.
Serving as medical research director of TORQUE, Dr. Tjoe leads clinical- and lab-based
research, including studies of the effects of exercise after cancer treatment through the
Team Phoenix cancer survivorship group.

4

Published
Manuscripts

1

Published
Abstract

CLINICAL RESEARCH

LABORATORY RESEARCH

Studies have found that women who are overweight or obese when their
breast cancers are diagnosed have a greater risk of having their cancers
recur compared to women who were of a healthier weight. Through
a Phase III multicenter trial sponsored by Alliance for Clinical Trials in
Oncology, researchers seek to determine the effect of a supervised weight
loss program plus education materials versus education materials alone
on preventing invasive breast cancer from coming back (clinicaltrials.gov
identifier: NCT02750826). They will test whether overweight or obese
women who take part in this supervised weight loss program after being
diagnosed with breast cancer have a lower rate of cancer recurrence than
women who do not participate in the program.

Employing a bedside-to-bench approach, TORQUE scientists leverage
clinical questions and patient data in the electronic health record against
tissue and blood samples stored in Aurora’s Biorepository and Specimen
Resource Center to conduct longitudinal studies in search of indicators for
breast cancer.

In another trial, Aurora Health Care researchers are studying whether
magnetic resonance imaging (MRI) and genetic testing may help
determine if removal of the breast containing the precancerous lesion is
necessary for patients with ductal carcinoma in situ. The National Cancer
Institute Phase II clinical trial sponsored by ECOG-ACRIN Cancer Research
Group will track candidates deemed eligible for breast conservation,
based on standard imaging and physical exam, who undergo mastectomy
after MRI (clinicaltrials.gov identifier: NCT02352883). Tissue from
consenting subjects who have surgery will be analyzed for genetic
characteristics to guide therapy.

Based at Aurora Sinai Medical Center, Dr. Tjoe collaborates internally
with researchers in Discovery Laboratory. Senior research scientist
John Richards, PhD, has focused some of his efforts on understanding
the immune response using breast cancer cell lines. One study focused
on using the chemotherapy drug tamoxifen to increase expression of
human epidermal growth factor (HER2), making it more susceptible to
the chemotherapy drug trastuzumab. This led to enhanced immunity to
more effectively kill tumor cells. However, in already functioning HER2
breast cancer cells, tamoxifen further activated HER2, but failed to
enhance immune function, which did not make them more susceptible to
trastuzumab. This suggested that although the immune system responds
to HER2 activated cells, there would be little benefit to increasing this
activation in patients whose HER2 cells are currently functioning.
The results of this study were published in August 2016 in Cancer
Immunology and Immunotherapy. The study was funded in part by an
Aurora Cancer Care Research Award, available because of donations from
the Vince Lombardi Cancer Foundation.
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Head and neck cancer (HNC) refers to
any cancer that develops in the throat,
nose, mouth, lips, voice box, sinuses, or
salivary glands. Approximately

90% of

HNC cancers are squamous cell carcinomas.
In general, these cancers have been linked
to use of tobacco and alcohol, and these
remain significant risk factors for the
development of HNC cancer.

In recent years, Human Papillomavirus
(HPV)-related oropharyngeal cancers
(cancers of the tonsils and tongue base)

BY THE
NUMBERS
Patients Diagnosed at Aurora
2016
Oral Cavity
67
Oropharynx
62
Major Salivary
Gland
14

Nasopharynx
3
Hypopharynx
12

oropharyngeal cancer is most frequently seen

Nasal/
Paranasal
8
Other
15

in younger adults who are otherwise healthy
and commonly are non-smokers and non-drinkers.

398

Larynx
57

have become increasingly common. It is now
the most common type of HNC. HPV-related

HEAD & NECK
TOTAL

Thyroid
160
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Multidisciplinary
Clinic Visits

Jan-Dec
MULTIDISCIPLINARY CARE DRIVES BETTER OUTCOMES
Regardless of cause, due to the complex anatomy of the head and neck and
the potential for life-altering effects from the cancer or its treatment, the
treatment of these cancers is multifaceted and relies on the expertise of many
uniquely qualified clinicians. In 2014, Aurora Health Care launched a
multidisciplinary effort to facilitate high-quality care for those with head and
neck cancers. As part of an integrated health system spanning 15 hospitals
and 150 clinics, this coordinated effort allows every patient in the system to
receive expert input regarding best practice treatment based on type, location,
and stage of cancer in order to develop an individualized plan based on their
specific needs.
Weekly dedicated HNC conferences are structured to allow for caregivers
across the Aurora Health Care system to participate in a multidisciplinary
discussion of each case. This forum allows for alignment with national
guidelines of best practice, education of all toward new treatment strategies
and upcoming clinical trials, coordination of supportive services, and problem
solving toward barriers to timely and integrated care. All of this with the
focus of identifying and ensuring the highest quality and care for each
individual patient.
In addition, our Head and Neck Cancer Multidisciplinary Clinic (MDC) allows
those with HNC to receive a comprehensive evaluation and consensus opinion
from several disciplines in a single appointment. This approach allows patient
discussion with the entire team about management of their specific diagnosis
and the opportunity to explore the pros and cons of their options. This format
allows for the early identification and integration of care strategies and has
been proven to reduce delays in care. We see our HNC patients throughout
their journey from diagnosis, through treatment, after treatment, and into
survivorship. This MDC clinic team of dedicated HNC specialists is comprised
of HN Surgical Oncologists: Steven Dankle, MD and Michael Nordstrom, MD;
Medical Oncologist: Robert Taylor, MD; Radiation Oncologists: Perry Gould, MD
and Jeffrey Kittel, MD; Physicians Assistants: Kate Rabe, PA-C and Sara
Bjorklund, PA-C; Registered Dietitian: Jane Collins, RD; Speech
Therapist: Tanya Zinski-Loomer, MD, SLP; Cancer Nurse Navigator:
Valerie Werner, RN BSN OCN.
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2017
222 Visits

Jan-Dec

2016
188 Visitss

RESEARCH HIGHLIGHT
Cancer Nurse Navigators and Multidisciplinary Video Conferences
for Head & Neck Cancer — Poster Session at American Society
of Clinical Oncology (ASCO) National Oncology Forum Meeting
A poster entitled "Cancer Nurse Navigators increase physician
engagement in multidisciplinary discussions prior to head and neck
cancer treatment" was published by the American Society of Clinical
Oncology (ASCO) which validated the benefits of our multidisciplinary
approach. The poster, authored by Valerie Werner, RN, BSN, Anne
Barry-Weers, RN, MS, James Weese, MD, FACS, and Martin Corsten,
MD, FACS, presented the findings that Cancer Nurse Navigators and
system wide high-definition video conferencing facilitate multidisciplinary
collaboration in treatment of head and neck cancers. This increased
engagement, changed practice patterns, aligned the institution with
best practice guidelines, and aided in therapy selection for the
best possible patient outcomes.

Jan-Dec
Jan-Dec

2017
366 Cases
Discussed

2016
336 Cases
Discussed

Multidisciplinary
Cancer Conferences

PARTNERSHIP WITH NEUROSURGERY MINIMIZES TREATMENT IMPACT: EXPAND ENDONASAL APPROACH (EEA)

Revolutionizing the way brain surgeons access
the skull base and upper cervical spine in a less
invasive way.
During endoscopic endonasal surgery, a neurosurgeon and an otolaryngologist work
together to enter the skull base through the nose. This minimally invasive technique
eliminates the need for external incisions and brain retraction. By removing the back
half of the nasal septum and the bone in front of the sphenoid sinus, surgeons can
reach the skull base.
Tumors are then removed with the help of high-definition optics and an endoscope.
Finally, the skull base is reconstructed using a flap of the septal membrane — which
seals off the brain from the nose — helping prevent complications.
The Expanded Endonasal Approach (EEA) allows access to skull base tumors minimizing
the complications that can be seen with open skull base surgery, which include infections
associated with large scalp incisions and the side effects seen with brain retraction.
Many patients undergoing EEA spend only one to two days in the hospital, and recovery
time at home can be much shorter than for open skull base surgery. In addition, there
are many scenarios in which EEA causes less disruption of critical nerves during skull
base surgery.

The EEA is used to perform minimally invasive surgery for cancers of
the head and neck such as:
•
•

•
•

Brain tumors
Cancers of the sinus
(squamous cell, sphenoid
sinus carcinomas, adenocystic, and metastatic)
Meningiomas of the
skull base
Pituitary tumors		
(including pituitary		
adenomas, acromegaly,
prolactinomas, and		
pituitary apoplexy)

•
•
•
•
•

Olfactory 			
neuroblastomas
Rathke’s cleft cysts
Skull base tumors and
cysts
Chordomas and 		
chondrosarcomas
Orbital tumors and		
Graves’ disease
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With 480 new primary tumors and another 1,200 cases of metastatic
brain cancer expected in the state of Wisconsin every year — including
926 new deaths from the disease — Aurora Health Care has made a
commitment to the early diagnosis and innovative treatment strategies
of primary and metastatic brain tumors of all kinds.
Based on American Cancer Society registry data, 7.4 people out of every
100,000 will be diagnosed with brain cancer next year in Wisconsin,
which is more than the 6.6 expected across the United States.
A distinctive feature of the Aurora Neuroscience Innovation Institute
(ANII) is the multidisciplinary approach to brain tumor management
used at every stage of treatment and diagnosis. Our specialized team of
neurosurgeons, neuroradiologists, neuro-oncologists, and radiation
oncologists work collaboratively with the added expertise of
neuropsychology, head and neck oncology, neurology, pathology, and
many others, including cancer nurse navigators, neuroscience advanced
practices nurses and physician assistants. We treat our patients as
members of the care team, keeping them actively involved in all
decision-making to ensure all questions and concerns are evaluated and
taken into account. The patient is the most important shareholder in the
decision-making treatment process.
Multidisciplinary cancer conferences and multidisciplinary clinic visits are
available weekly for patients with neuro cancers.

Multidisciplinary
Clinic Visits

Jan-Dec

2017

Jan-Dec

2016

BY THE
NUMBERS
Patients Diagnosed at Aurora
2016

Brain
(Benign)
39

Brain
(Malignant)
68

Other
399

BRAIN & CNS
TOTAL

506

505 Visits

666 Visits
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WHY MOLECULAR PROFILE PROTOCOLS ARE IMPORTANT
Nearly 80% of primary malignant brain tumors are gliomas, a majority of these fall into the category of glioblastomas (GBM’s),
the most aggressive form. To facilitate the initial diagnosis and timely treatment of GBM’s the neuro oncology team has
committed to the development of molecular profiling protocols. The molecular profiling protocols or tumor markers are
automatically ordered by the Pathology Department for every surgical specimen with a diagnosis of glioma.
Molecular profiling is a method of testing that looks at each person's cancer tumor and studies the genetic characteristics as well
as any unique biomarkers. The information gathered is used to identify and create targeted therapies that are designed to work
better for a specific cancer tumor. Targeted therapies can be more effective, with fewer side effects and a better chance of
curing the cancer and/or controlling the tumor growth. As Aurora Health Care researchers learn more about genetic and
molecular differences of cancer, additional targeted therapies will be developed and continue to provide the neuro-oncologist
the information needed to help determine which patients will benefit from a specific treatment as well as help in the
determination of survival.

USE OF CLINICAL PATHWAYS TO FACILITATE MULTIDISCIPLINARY CARE
In addition, several clinical pathways have been developed for the management of patients with malignant brain tumors. These
pathways have been embedded into the Electronic Medical Record (EMR) and designed to provide a structured, multidisciplinary
plan of care that is evidence-based for a specific group of patients with a predictable clinical course. The pathways require input
and interventions from multiple professionals working together as a team providing patients the best care while optimizing
clinical quality and outcomes.
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BRAIN MAPPING

Advanced brain mapping technology lets our
team of experts see the precise location of
individual brain functions — speech, memory,
and movement — in order to help determine
the most appropriate treatment.
Brain mapping is a critical tool used by neuroscientists to plan surgeries for brain
tumors. If surgery is needed, brain imaging technology may be used before and
during a procedure to differentiate healthy brain matter from diseased tissue. It
can also be used to define a surgical or navigational strategy to help avoid injury to
portions of the brain needed for critical functions.
Diffusion tensor imaging with white matter tractography is one type of brain
mapping. It uses state-of-the-art technology to create a 3D map of the brain,
which shows the location of nerve fibers that control speech, memory,
cognition, and thought — all of the things that make you…you!
Brain mapping is a fundamental element of our minimally invasive methodology
for treating subcortical tumors and cysts that were often considered otherwise
inaccessible. It provides advanced assistance with determining the best surgical
approach to remove a tumor.

NOVEL TREATMENT OPTIONS FOR PATIENTS WITH GBM

Aurora has performed more
optical robotic brain surgeries than

and
Aurora Neuroscience
Innovation Institute was the first
anyone in the world to date,

Optune is a wearable, portable, FDA-approved device treatment placed on the
scalp for adult patients (22 years of age or older) with a new diagnosis of GBM
(used with a chemotherapy called Temozolomide) or if a tumor has come back,
it can be used alone as an alternative to standard medical therapy that is as
effective as chemotherapy with fewer side effects. When Optune is turned on,
it creates low-intensity electric fields, called Tumor Treating Fields, or TTFields.
TTFields help slow or stop glioblastoma cancer cells from dividing and may also
cause some of them to die. Optune uses four adhesive patches, called transducer
arrays, to deliver therapy. These transducer arrays are applied to the scalp and are
connected to the device and battery. The transducer array placement is determined based on each patient's MRI results to help maximize the effect that TTFields have
on the tumor. TTFields work when cancer cells are dividing and do not disrupt healthy resting cells. Because TTFields do not enter the bloodstream, like a drug, they
have not been shown to affect cells in other parts of the body. The most common (≥10%) adverse events seen when using Optune alone were scalp irritation from device
use and headache.

in the world to deploy a unique 3-D brain
mapping platform for

patient care.
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Cancer Rehabilitation
Cancer rehabilitation addresses the musculoskeletal, cardiopulmonary,
and functional impairments expected with cancer treatment,
survivorship, advanced disease, and end of life. The most common of
these problems include fatigue, pain, weakness, stiffness, fibrosis and
scarring, difficulty walking, and the overall inability to function normally.
Depending on the type of cancer, additional problems can occur
including poor balance, swelling, lymphedema, incontinence, weight
loss or weight gain, problems swallowing, cognitive issues, and sexual
health issues.

Rehabilitation and Survivorship
Rehabilitation in cancer survivorship helps patients deal with the late
and long-term effects of cancer treatment and helps them get back to
being as healthy as possible, as fast as possible. Rehab treatment plans
can help reduce, eliminate, and prevent problems such as fatigue, heart
damage from chemotherapy, neuropathy, aching muscles and joints, scar
tissue, fibrosis, and change in body weight. Rehab therapists will also
develop plans to help cancer survivors meet the American Cancer
Society’s activity recommendation of 150 minutes per week of exercise.

Rehabilitation and Cancer Surgery
Rehabilitation therapists intervene with treatment before and/or after
surgery to restore pain free movement, physical strength, scar mobility,
and function. With rare exception, post-operative cancer rehabilitation
should return people to their full pain free pre-operative level
of function.

Rehabilitation and End of Life
Exercise has been shown to be both safe and effective for people
with advanced cancer. Treatment plans and goals aim to keep the
person as independent, strong, and mobile as possible, and will be
centered on pain reduction, safe mobility instruction for the patient
and family, maximizing quality of life, and reducing the risk of falls and
hospital stays.

Rehabilitation and Chemotherapy
Research has shown that rehabilitation during chemotherapy is not only
safe, but also effective in treating many chemotherapy related problems,
helping patients stay stronger and suffer less physical loss. It works to
reduce fatigue, muscle and physical weakness, minimize the effects of
neuropathy, maintain good balance, and get to or maintain a healthy
body weight.
Rehabilitation and Radiation
The best way to minimize fatigue and weakness during radiation is
through a strengthening and aerobic exercise program. Rehab therapists
can also help prepare the patient’s body for the radiation position. Long
term home stretching programs will also be developed to combat the
tightness and fibrosis common months or years later.

REHABILITATION AND INSURANCE COVERAGE
•

Cancer rehabilitation evaluations are covered by all
insurance plans

•

Prior authorizations are performed for all patients

•

Insurance coverage is discussed by the therapist and patient

•

Rehabilitation therapist develops treatment plans within the
guidelines of insurance coverage and patient wishes

The National Accreditation Program for Breast Centers (NAPBC),
the Commission on Cancer (CoC), and the National Comprehensive
Cancer Network (NCCN) recognize the importance and benefits of
cancer rehabilitation and recommend it begin at cancer diagnosis.
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Integrative Medicine
Integrative Therapies
Aurora Health Care is a leader in the field of integrative medicine, offering
a healing-oriented approach for the whole person. In patients with cancer,
palliating symptoms associated with cancer or its treatment are a major
priority. Aurora has found that integrative approaches add benefit beyond
maximal medical therapy in reducing symptoms, improving quality of life,
and potentially facilitating continued cancer treatment. Acupuncture,
aromatherapy, massage, and Reiki are integrative therapies offered to
reduce symptoms of pain, neuropathy, nausea, and stress related to
treatment. Patients want their providers to know they are getting
integrative therapies and feel it is important for the care team to have this
information about them. Aurora’s integrated care model makes this
possible. Access to integrative therapies is made possible through the
Aurora Health Care Foundation, and by generous philanthropic donations
which support low cost and free access to integrative therapies.
Integrative Medicine Providers
Fellowship trained integrative medicine physicians and advanced
practitioners are trained to provide a combination of modern and
conventional medicine with holistic medicine. Our fellowship trained
providers partner with patients and their oncology specialist to offer the
following as needed:
•

Integrative treatment plans during or after cancer treatment
which incorporate
		- dietary strategies
		- mind-body therapies
		- integrative therapies
•
Advise patients regarding the risks of alternative cancer treatments
•
Advise patients about nutritional and other lifestyle strategies for
reducing risks of re-occurrence
•
Teach those at risk for cancer about lifestyle strategies for reducing
those risks
Acupuncture
Acupuncture is a traditional Chinese medicine system of natural healing
that has been practiced for more than 4,000 years. This ancient healing
art does not use drugs or surgery to treat the body. Rather, fine sterile

needles are inserted into specific points on the body to promote healing
and reduce emotional stress. There is generally no pain associated with
the insertion of these very fine needles. Several studies have
demonstrated that acupuncture activates the pathways between the
nervous and endocrine systems.
At Aurora Health Care, our acupuncturists work closely with Aurora’s
oncology specialists to provide competency-driven individualized care to
meet each patient’s specific needs.
Massage Therapy
Massage therapy is defined as the use of one’s hands to apply pressure
and motion on another person’s skin and underlying muscle for the
purpose of physical and psychological relaxation, improvement in
circulation, relief of muscle tension, and other therapeutic benefits.
Research studies have found that individuals with cancer who use regular
massage report less anxiety, pain, and fatigue.
Reiki Therapy
Reiki (“ray-key”) is a Japanese word for universal life-force energy and a
simple yet powerful Eastern medicine healing technique. A trained Reiki
practitioner helps to guide the flow of energy through a person’s body.
This energy flow, or connection, enhances the body’s power to heal. It
also quickens relaxation and reduces stress.
Within many of our Aurora Cancer Care clinics, Reiki treatments are
offered to patients receiving chemotherapy while seated in comfortable
recliners, fully clothed. Aurora’s volunteer Reiki practitioners provide
patients a gentle touch with specific hand positions on or above the body
to guide the flow of healing energy. There are approximately 30 Aurora
volunteers who are Reiki certified providing complimentary Reiki in the
chemotherapy infusion bays across 11 of the 19 cancer centers. Our volunteers are actively collecting outcomes from their sessions, thus allowing
us to provide data to the cancer centers about this service. In addition,
all of our massage therapists are trained in at least Reiki Level One, and
some of them offer Reiki sessions for payment at various clinics around
the area.
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BY THE
NUMBERS
Outcome data for the use of massage and acupuncture at Aurora Cancer Care clinics reveals the following post-treatment responses:

Acupuncture Post-Treatment Responses

90%

of patients report a
reduction in pain

89%

of patients report a
reduction in neuropathy

91%

of patients report a
reduction in nausea

92%

of patients report a
reduction in stress

Massage Post-Treatment Responses
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86%

of patients report a
reduction in pain

76%

of patients report a
reduction in neuropathy

65%

of patients report a
reduction in nausea

92%

of patients report a
reduction in stress

Aromatherapy
Aromatherapy is the art and science of using pure essential oils extracted from natural plants and flowers. Essential oils are used to calm, balance, and give
energy to the body, mind and spirit. At Aurora Health Care, we use specific essential oils for patients with cancer to enhance well-being. Nurses and massage
therapists working within Aurora Cancer Centers are trained to provide patients with safe and effective use of essential oils. We also provide information on
how they can be used in daily life. Some of the oils that can help cancer survivors are listed below. For more information, patients can speak to their cancer care
team or contact Aurora Integrative Medicine.

Lavender is known to relieve insomnia and reduce anxiety and is
the perfect choice to soothe the soul. It also works to eliminate
airborne bacteria and viruses, helping people stay healthy and well.

Mandarin is one of the gentlest and safest essential oils. Its calming influence promotes sleep, reduces irritability and lifts moods. It is also used to
soothe digestion and reduce nausea.

Peppermint is a refreshing and mentally stimulating essential oil. Its minty
fresh scent is easy to recognize and can also help with sinus congestion,
nausea, vomiting, and headaches.

71

Palliative Care
Living with a chronic or complex illness requires unique support. Conditions like cancer require care that addresses
both medical and emotional issues. Our Palliative Care Program helps you manage your symptoms for increased comfort and
quality of life.
Palliative care is a special kind of care for people who have a serious medical issue. It focuses on relieving pain and other symptoms
while addressing the psychological, emotional, and spiritual needs of patients, their family members, and caregivers.
The goal of palliative care is to provide the best quality of life for individuals by ensuring comfort and dignity. It is not
disease- or age-specific. Palliative care benefits any individual with an advanced disease or life-changing condition and is
appropriate for patients of all ages, from infant to elderly.
Benefits of palliative care:
•
•
•
•
•
•

Better understanding of the patient's condition and their choices for medical care
Emotional support for patients and their family
Relief from distressing symptoms such as pain, shortness of breath, fatigue, constipation,					
nausea, loss of appetite, and troubled sleep
Ensure medical care is in line with patient’s wishes
Anticipate future problems and needs
Improved ability to carry on with daily life

A typical palliative care team includes a physician, nurse practitioner, social worker, spiritual counselor, pharmacist, nurses,
and specialists. If needed, a therapist, dietitian or home health aide may be added to the team as well.
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Emotional/Spiritual Support
EMOTIONAL/SPIRITUAL SUPPORT
Supportive Counseling Services
A diagnosis of cancer greatly impacts a person’s life. It can change
how a patient feels, affect relationships with family and friends, and
disrupt plans for the future. Many people find that in this
difficult time, anxieties can be eased through caring, sensitive support
from counseling professionals. Aurora Cancer Care supportive
counselors understand that the medical aspect of cancer is only
part of the disease’s impact. While medical expertise is essential, our
counselors realize that professional support to help cope with the
emotional aspect is invaluable as well. To help patients and their family
face the disease and fight it, we offer a wide variety of comprehensive
counseling services, including individual, family, and group counseling,
and assistance with fatigue, pain, insomnia, appetite disturbances,
anxiety and depression.
Social Services
A cancer diagnosis can result in concerns related to work, finances,
insurance coverage, advanced care planning, and the need to
identify and link with community resources. The Aurora Cancer Care
team includes social workers who understand these challenges and are
available to provide support — including help with financial counseling
— when needed.
Spiritual Care
In times of crisis and uncertainty, spirituality can be an important
strength. We have chaplains who are available to provide a supportive
presence to patients, their family, and friends. They offer consultation
and counsel regarding spiritual, emotional, and ethical matters, as well
as provide respectful spiritual support and care to people of all faiths
and beliefs.
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Fertility
Preserving Fertility Before Cancer Treatment
Cancer and its treatment may affect the body, including the
reproductive system, in many ways. Because the medicines and
treatments that work to kill cancer cells can also affect other cells and
organs in the body, these treatment options may interfere with future
fertility by damaging sperm, eggs, or other reproductive organs. Factors
such as the type of cancer diagnosed, chemotherapy, radiation therapy,
and cancer surgery can all lead to potential reproductive problems.
Cancer diagnosis: Having cancer can lead to infertility. For example,
testicular cancer and Hodgkin’s lymphoma can lead to low sperm counts
in some men even prior to starting cancer treatment.
Chemotherapy: Can be damaging to both sperm and eggs. Use of
alkylating agents, platinum-based agents, and some other
chemotherapy drugs can have a detrimental effect on fertility. Individual
factors such as age at the time of cancer treatment, type of
chemotherapy drugs used, and the total dose of these drugs will
determine the degree of damage to the sperm or eggs.
Radiation therapy: Radiation therapy can also damage the reproductive
system. Radiation aimed at the pelvis can have a direct effect on the
ovaries or testicles which can lead to infertility. Radiation to the brain
can affect hormone production and also result in infertility.
Cancer surgery: Surgery for cancer involving the testicles, ovaries,
uterus, cervix, or surrounding structures in the abdomen or pelvis can
also cause permanent infertility.
Fertility Preservation for Men
Sperm banking involves collecting a sample of semen and freezing it.
Sperm must be banked before any chemotherapy or pelvic radiation
therapy begins in order to avoid storing damaged sperm. Sperm can
be collected daily or every other day within a seven-day time frame for
adequate collection.

Sperm banking may be worthwhile even if the sperm count is low or
when only one sample can be stored. This sperm can remain frozen
indefinitely and can be thawed later and used for intrauterine
insemination or in vitro fertilization.
Fertility Preservation for Women
There are several ways to attempt to preserve fertility in women prior
to their cancer treatment, but most remain experimental with unknown
success rates. Proven methods of fertility preservation include embryo
freezing and egg freezing.
Embryo freezing is a proven successful method for preserving fertility.
Because it requires sperm, this option is best for women who are
married or those who have a committed partner. Embryo freezing is
also an option for women willing to use donor sperm to fertilize their
eggs. Egg freezing is a newer option for those women who prefer to
freeze unfertilized eggs. These eggs would then be available for future
fertilization using a partner’s or donor sperm. The process of embryo
or egg freezing can take a maximum of two to four weeks.
Testing Fertility After Cancer Treatment
A semen analysis is a simple test that can be performed in men after
cancer treatment to check for sperm production. It can be uncertain
when fertility will return in men, and it may take years for sperm
production to restart after cancer treatment.
For women, the return of menstruation may or may not predict future
fertility. A reproductive specialist can check blood tests for hormone
levels and perform an ultrasound to estimate the quality and number
of eggs remaining in the ovaries.
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Precision Medicine
ONCOLOGY PRECISION MEDICINE
The Aurora Cancer Care Oncology Precision Medicine Clinic
provides a multidisciplinary approach to treating cancer,
especially cancers that are resistant to standard treatments.
Our clinic is a collaboration with medical oncologists,
pharmacy, pathology, research, radiology, and genetic
counselors to provide patients with treatment options
beyond radiation or chemotherapy. This approach is
giving additional treatment options to health care providers
and some cancer patients.
Aurora Cancer Care Oncology Precision Medicine Clinic is
the first clinic in Wisconsin with access to Syapse, a precision
medicine platform that offers physicians access to clinical and
molecular data aggregated in a central data site.
Precision medicine broadly defined can take individual
variability into consideration for prevention, diagnosis, and
treatment. In the Oncology Precision Medicine program
cancer molecular profiling explores the molecular makeup
of a person’s cancer tumor. If a patient has a tumor with an
actionable molecular change, then treatments can be offered
that target that persons molecular cancer signature.
Targeted precision medicine therapies are the standard of care
in some cancers — e.g. anti-Her2 therapy in breast cancer and
BRAF inhibitors in melanoma. In other cancers, there may be
clinical data or a strong rationale for using targeted therapy.
Outcome data are being collected on the molecular changes
found in our cancer patients and the clinical responses.
Patients can discuss with their health care teams if precision
medicine is right for them.
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To ensure Aurora Cancer Care remains at the forefront of precision medicine, we have adopted use of the Syapse platform which will share our de-identified data
with other health care systems so that we can see the treatment results of genetically similar tumors in patients across the country.
Syapse offers the physicians at Aurora Cancer Care the opportunity to share information, in real time, that they gather about different molecular genetic
characteristics of cancers and information about the targeted therapies and patient results while preserving patient privacy.
To expand the reach and effectiveness of our precision medicine efforts, Aurora has joined the Oncology Precision Network (OPeN). It’s a leading data-sharing
network created specifically for not-for-profit health care systems such as Aurora.
The information shared on OPeN becomes part of a database that’s available to a national network of health care systems and hospitals. Through OPeN, hundreds
of cancer experts will be able to share results of the precision medicine treatments of thousands of patients. The privacy and security of patients is a priority, so
personally identifiable patient information is not available on the network.
The information that is shared by the network can benefit other patients who may have genetically similar tumors to those already successfully treated elsewhere.
This can save valuable time in getting patients effective treatment sooner. Currently this information can take years waiting for publication or never be published,
particularly if there was no response seen. Participation in Syapse provides us with data about similar patient responses so we can more effectively advise our
patients based on current effects of a given drug.
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RESEARCH HIGHLIGHT
MATCHING CANCER THERAPIES TO GENETIC ABNORMALITIES
Although the dawn of targeted cancer therapies began in the early 1960s, more recent understanding of cancer cell biology has driven new treatments that
have positively affected outcomes in many types of cancer. Building on this understanding, the 2016 Precision Medicine Initiative allocated $70 million to the
National Cancer Institute (NCI) to help identify genetic causes of cancer and develop more effective cancer therapies. As part of the initiative, NCI sponsored
the Molecular Analysis for Therapy Choice, or NCI-MATCH (clinicaltrials.gov identifier: NCT02465060).
For this multicenter, Phase II clinical trial, Aurora Health Care Cancer Centers are actively recruiting subjects who are 18 years and older with advanced solid
tumors, lymphomas, and myelomas that are no longer responding or never responded to standard therapy. Participant tumor samples are screened for
genetic abnormalities, such as mutations, amplifications, or translocations. “Genetic tests look at the unique genetic material of patients’ tumor cells,” said
Rubina Qamar, MD, local principal investigator for Aurora. “Patients with genetic abnormalities may benefit more from treatment that targets their tumor’s
particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas,
or multiple myeloma.”
Targeted treatments are based on the molecular makeup of the tumor rather than on the tumor type. Researchers will match the subjects with a drug
intended to target the specific gene abnormality. “This trial is a type of basket trial designed with the flexibility to open and close arms for different study
drugs,” Dr. Qamar said. “The trial has included many more drugs for testing than most other clinical trials and is including even more drugs as additional arms
are added.” Dr. Qamar stressed the importance of genetic screening in patients with cancer. “Since the first validation of oncogene-targeted therapy in chronic
myelogenous leukemia, it has been appreciated that treating the principal driver oncogene has a powerful impact,” Dr. Qamar said. “However, for subsequent
successful applications of molecular targeted therapy, the presence of the target oncogene requires genomic prescreening of a patient’s tumor.”

VIA PATHWAYS
VIA Oncology provides physicians with evidence-based pathways for the
treatment of cancer through collaboration with University of Pittsburgh
Medical Center, Dana Farber Cancer Institute at Harvard, Indiana University,
University of Chicago, and the University of Oregon, among others.

James Weese, MD, et al. explain, “VIA’s decision support algorithms are
evidence based, and updated quarterly by both academic and community
oncologists. Regimens are based on efficacy, then toxicity, and finally cost.
When available, a clinical trial is the first recommended option.”

It allows us to see what treatment protocols are most used for a given
population and ensures consistency of evidence-based care among
physicians in an increasingly complex field.

The goal of Aurora Cancer Care in implementing VIA pathways is to
develop value-based models of care. This is accomplished by using the
tool to provide the best, most effective treatment plans and increase
clinical trial enrollment.

Aurora Cancer Care’s results with VIA implementation were published in an
abstract accepted at the 2016 Annual American Society of Clinical
Oncology (ASCO) Meeting.
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Hereditary Cancer Prevention & Management
The Aurora Hereditary Cancer Prevention and Management Center (HCPMC) was established in May 2015. The concept of the clinic is to provide continuity of
care for individuals and families with complex or difficult hereditary cancer conditions. Michael Mullane, MD, and the Aurora Genomic Medicine Department have
collaborated to establish this program, aimed at providing preventive care to the highest risk individuals. At the Aurora HCPMC, patients and at-risk
relatives undergo an evaluation, discuss management and prevention recommendations, and participate in outcomes research. This clinic is the first of its
kind in the Midwest and continues to be the model for health care organizations looking to establish hereditary cancer management clinics around the country.
Since its inception, Aurora has gone from a twice a month clinic to a weekly clinic. It is now available at Aurora St. Luke’s Medical Center and Aurora BayCare
Medical Center. In the first two years, 186 patients were seen in the clinic. Fifty-five of these patients were family members of the initial patient found to have the
disease/gene mutation. Medical management and surveillance plans were initiated for appropriate patients. These plans were tailored to the individual and
family according to their cancer risks associated with their particular gene mutation. Many patients required ongoing surveillance, including serial imaging
studies, laboratory tests, referrals to other specialists, and some further genetic testing.

Medical Management For All Patients
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The clinic is designed specifically to address the needs of patients with rare and complicated cancer risks. Patients with a single gene
mutation tend to have multi-organ system risks. Additionally, in the first two years, patients with risks associated with 25 different genes
were seen and evaluated.
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Although the HCPMC is a relatively new clinic, the medical management
plans implemented have already yielded some important outcomes. Four
cases are described here.
•

•

Thirty-three year old unaffected male reluctantly came to HCPMC after
his mother was found to have a CDH1 mutation. He tested positive
for the familial mutation. We referred him to GI surgical oncology for
prophylactic gastrectomy. He was found to have Stage I diffuse gastric
cancer, and required no further treatment.
Thirty-seven year old unaffected female came to HCPMC after testing
positive for a familial SDHB mutation. Screening was initiated including
whole body MRI, which revealed a 2.5cm carotid body paraganglioma.
Surgery pending.

•

•

Forty-four year old found to have a PTEN mutation after a breast
cancer diagnosis and treatment. She came to the HCPMC after a
colonoscopy revealed harmartomatous polyposis and GI recommended
colectomy. We found a GI willing to do serial colonoscopy. We initiated
high-risk breast screening. A second primary breast cancer was found.
Forty-three year old came to the HCPMC after she was identified to
have two different TP53 mutations, detected at low allele frequencies.
She had been given a diagnosis of Li Fraumeni prior to coming to our
clinic. We initiated a confirmatory algorithm including cascade testing
of children, single site testing in skin fibroblasts, normal breast tissue,
and cancerous breast tissue. Both mutations were found only in tumor
specimen. Thus, the diagnosis of Li Fraumeni was disproven.

Percent of Patients by Gene Mutation
2016
4%

Mutation
Types

FLCN

RAD50

BRCA1

MRE11A

24%

CHEK2

2%

PTEN
MUTYH
MSH6
MSH2
FH
CFTR
CDKN2A
CDH1
BRIP1

14%
3%

BRCA2
PALB2
SDHA

MEN1

1%

BARD1
APC
SDHB
TSC1

6%

TP53

7%

MLH1

5%

PMS2

11%

ATM
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Cardio-Oncology
THE KAREN YONTZ CENTER FOR CARDIO-ONCOLOGY
Over the past two decades, there have been tremendous advancements in the care of people with cancer. This has resulted in more people being survivors of
their cancer and living longer with their disease than in the past. Over the same time, there have been great advancements in cardiology, resulting in improved
diagnostics and improved care. The confluence of the advancements in these two areas has resulted in more patients with cardiovascular diseases and
coexisting cancers, and more patients with cancer developing cardiovascular disease both as a consequence of their cancer treatment and unrelated to their
cancer treatment. This has created new challenges and opportunities in the care of these patients.
At Aurora Health Care, this was recognized several years ago and has catalyzed the development of a true collaborative effort between Cardiovascular and
Cancer Service Lines through the launch of the Karen Yontz Center for Cardio-Oncology. The program’s development is thanks to the support of our donors,
Mr. Ken Yontz, the Aurora Health Care administration, the Vince Lombardi Cancer Foundation, and our many colleagues from across the health care spectrum,
including: pharmacy, nursing, and information technology.
The Karen Yontz Women’s Cardiac Awareness Center, located inside Aurora St. Luke’s Medical Center, has been educating women about heart disease for more
than a decade. The new Karen Yontz Center for Cardio-Oncology at Aurora Health Care is an Aurora system-wide program, and the first of its kind, with the
unique collaboration between the cardiology and cancer service lines. This multidisciplinary program monitors patients who have received or are receiving
cancer treatments that could potentially impact the cardiovascular system. This permits the patient to receive treatment that could prevent or reduce the side
effects resulting from cancer treatments and allows the treatment team to modify treatment plans as appropriate. It will also explore innovative ways to better
identify patients at greatest risk to develop cardiovascular toxicity and develop methods to reduce or prevent these ill effects.
Patients entering this program will undergo a standardized risk assessment that includes laboratory biomarkers, imaging, and clinical care throughout cancer
treatment for the purpose of detecting and avoiding cardiotoxicity. “Cardiologists within the cardio-oncology program work with oncologists throughout the
Aurora network from the time of cancer diagnosis if the risk of cardiotoxicity is present,” explained Vinay Thohan, MD, who directs the program with Bijoy K.
Khandheria, MD. A baseline evaluation is performed to assess patient factors such as high blood pressure, diabetes, or stroke, and family and social history are
analyzed to determine the patient’s risk of developing cardiovascular toxicity during cancer treatment. Since opening in the Fall of 2016, the center has helped
over 200 patients before, during and after cancer treatment to treat, minimize, or prevent cardiovascular effects. “The most important goal is for patients to
complete lifesaving cancer treatments while maintaining good heart health,” says Dr. Thohan.
The collaboration helps oncologists and cardiologists refine their treatment plans. The center uses risk models, 3D/4D/strain echocardiography, and biomarkers
to find those patients who are at the greatest risk of developing cardiac toxicity so their physicians can individually tailor drug dosing and cardiac monitoring
when using those specific drugs. “Being aware that a patient is at high risk for cardiac dysfunction during or after cancer treatment allows us to take a more
aggressive approach to surveillance and treatment at the earliest stages,” Dr. Thohan said. Medical Oncologists Charles Bomzer, MD and Rubina Qamar, MD
along with their colleagues have collaborated with Drs. Thohan and Khandheria to develop this innovative collaborative care model. Dr. Qamar is also
conducting a study to determine if there are easily measurable parameters to predict the development of some of these side effects and more effectively
prevent them. In addition, Dr. Thohan has been awarded a grant from the Greater Milwaukee Foundation to investigate the genetic causes of heart disease
among patients who receive cancer treatments.
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RESEARCH HIGHLIGHT
PREVENTING ANTHRACYCLINE CARDIOTOXICITY WITH STATINS
Some chemotherapy drugs, such as anthracyclines, may result in irreversible heart failure. Statins, a class of drugs used to treat high cholesterol, may be helpful
in preventing congestive heart failure. The Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) clinical trial aims to discern whether the
statin atorvastatin decreases the chance of developing heart problems in women receiving anthracycline-based chemotherapy for breast cancer (clinicaltrials.
gov identifier: NCT01988571).
This trial is important for two reasons, the first is that it attempts to prevent heart failure with a statin, and the second is the trial uses Cardiac Magnetic
Resonance Imaging (MRI) to determine the amount of damage to the heart which is a much more sophisticated way of monitoring the heart. Aurora is one of
only a few sites that have the sophisticated cardiac MRI equipment to do this trial.
Aurora offers the only sites in the state of Wisconsin for this trial. Sponsored by Wake Forest University Health Sciences, in collaboration with National Cancer
Institute, the trial is being led locally by Thomas Saphner, MD.
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Oncology Volumes — New Cases (Systemwide)

VOLUMES (SYSTEMWIDE NEW CASES)
Source: Cancer Registry

2015

2016

2017*

PRIMARY SITE OF DISEASE
Breast
Prostate gland
Bronchus and lung
Melanoma and skin (T2+)
Blood and bone marrow
Colon
Urinary bladder
Meninges
Lymph nodes/lymphoma
Endometrium
Kidney, renal pelvis, ureter
Pancreas
Brain CNS
Thyroid gland
Liver and bile ducts
Rectum
Ovary
Unknown primary
Esophagus
Stomach
Adrenal and other endocrine
Vulva
Oropharynx

2015

2016

2017*

PRIMARY SITE OF DISEASE

1,283

1,314

1,342

867

937

954

886

890

939

437

407

524

516

487

326

418

482

425

331

408

372

373

390

345

331

330

301

287

310

350

294

312

297

209

202

201

166

142

168

159

160

146

132

153

173

137

120

141

115

128

117

72

70

127

86

83

96

85

83

86

90

79

51

61

63

86

75

61

56

Oral cavity
Cervix uteri
Larynx
Testis
Anus
Major salivary
Retroperitoneum
Musculoskelatal
Heart mediastinum
Other female genital organ
Head and neck undefined
Vagina
Nasal cavity and sinuses
Hypopharynx
Penis
Orbit
Nasopharynx
Other oral cavity
Peripheral nerves
Trachea
Totals

67

69

53

56

61

68

46

57

49

51

42

43

31

35

32

24

15

29
25

13

20

57

67

81

16

15

22

8

18

25

13

14

20
15

5

13

11

8

11

5

12

12

7

5

13

5

6

9

5

3

9

2

4

3

0

1

3

0

1

2

7,832

8,077

8,147

*estimated; complete data not available at time of publication
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